

Open Access
Volume 02, Issue 08 - 2026

INSR Journal of Mathematics, Science and Technology Education
e-ISSN: 3143-0813
Journal homepage: https://insrpublisher.com/insrjmste/

Research Article

DOI: 10.5281/zenodo.21760551

Digital Twin and Nano-Pharmacological Early Diagnosis in Colorectal Cancer: Adaptation of the 5th Law of Thermodynamics and Biorobotic Resonance with ELMAS's Theory of Thermodynamics

*** Emin Taner ELMAS [1] and Feyyaz AKÇİN [2]**

[1] Assistant Professor Dr., Vocational School of Higher Education for Technical Sciences, Division of Motor Vehicles and Transportation Technologies, Department of Automotive Technology, Iğdır University, Turkey & Graduate School of Natural and Applied Sciences - Major Science Department of Bioengineering and Bio-Sciences, Iğdır University, Turkey-76000

ORCID: https://orcid.org/0000-0002-7290-2308 | e.taner.elmas@igdir.edu.tr | +90 (0) 543 7336421

[2] Computer Technologies and Software Developer, Türkiye Iğdır University, Vocational School of Technical Sciences, Student Graduate of Computer Programming, Department of Software Engineering, Faculty of Engineering, Iğdır University Iğdır University - 76000

ORCID: https://orcid.org/0009-0004-6716-690X | feyyazakcin76@hotmail.com | +90 (0) 552 597 24 04

Submission Date: 20 April 2026 **Published Date:** 03 August 2026

Citation: Elmas, E. T., & Akçin, F. (2026). Digital Twin and Nano-Pharmacological Early Diagnosis in Colorectal Cancer: Adaptation of the 5th Law of Thermodynamics and Biorobotic Resonance with ELMAS's Theory of Thermodynamics. In INSR Journal of Mathematics, Science and Technology Education (Vol. 2, Number 8, pp. 1– 34). https://doi.org/10.5281/zenodo.21760551

Abstract

Colorectal cancer is a "silent" disease that can grow for years without showing any symptoms and is detected late. By bringing together software engineering, nanotechnology, and bioinformatics, this study proposes a 4-layer, software-driven "Smart Drug System" capable of catching and eliminating cancer while it is still in its silent stage.

The operational architecture of the system consists of the following four main layers:

1. Data Acquisition Layer: Performs real-time mucosal analysis inside the intestine using a capsule camera and deep-learning algorithms; diagnoses tumor tissue within milliseconds.
2. Rolling Key (Dynamic Update): To prevent the cancer from mutating and escaping the drug under treatment pressure, it updates the aptamer sensors on the surface of the nano-capsule programmatically at every dose, using instantaneous liquid-biopsy and NGS (Next-Generation Sequencing) data.
3. Logic Gate (AND Gate): To prevent the drug from harming healthy tissue, it will absolutely not initiate drug release unless all three of the following conditions are met simultaneously: an acidic environment ($pH < 6.5$), elevated MMP-9 enzyme levels, and presence of the target protein.
4. Digital Twin Platform: By transferring all of the patient's real-time processes to a virtual control panel (dashboard), it allows the clinician to monitor the treatment and, when necessary, to intervene in the autonomous process from outside (using magnetic fields/ultrasound).

Conceptual Framework and Thermodynamic Dimension:

The overarching framework that holds all these layers together is "ELMAS's Theory of Thermodynamics" (Energy,

Localization, Mutation, AND Gate, Signal) together with the 5th Law of Thermodynamics model. Integration is further achieved through the FM-Modulated Bio-robotic Resonance and Thermodynamical Interaction Method. The system uses the pH- and MMP-9-enzyme-dependent expression changes in the tumor microenvironment as thermodynamic driving forces, managing drug release with biomechanical precision by lowering the Gibbs free-energy barrier. With every component supported by independent clinical literature, this study offers a comprehensive biomedical platform for programmable and personalized medicine in cancer treatment.

Why Does This Study Possess Such Powerful Knowledge? (Highlighted Details)

- Coding the Drug Like a "Device": While conventional medicine operates on a "one dose for everyone" logic, in this proposed study the drug functions like an IoT endpoint (sensor-equipped hardware). Depending on the conditions of the biological environment it is in, it steers itself to a stable equilibrium through IF/ELSE logic.
- "Pushing a Software Update" to Cancer: As the tumor mutates, the drug is likewise redesigned and updated through bioinformatic analysis (Rolling Key), which theoretically breaks "drug resistance" — the biggest problem in oncology — completely.
- Regulation and Realism: The study does not confine itself to the theoretical framework alone

Colorectal cancer can remain asymptomatic for decades, and this remains true today. Existing screening and treatment tools are not sufficient on their own to close this gap. This study aims to develop a systematic, multi-layered response to this problem.

The system's core strength rests on the functional integration among its components: while each component has a limited scope of effect on its own, together they form a far more comprehensive biomedical platform. The Rolling Key cannot update a target without the capsule camera providing data; without the Rolling Key operating, the Logic Gate is forced to rely on an outdated profile; without the Logic Gate engaging, the drug may harm healthy tissue; and without the Smart Drug System and Digital-Twin-supported Imaging and Diagnosis, the course of the treatment process cannot be monitored. These four layers form a closed loop chain that functionally completes one another.

The framework of ELMAS's Theory of Thermodynamics and the 5th Law of Thermodynamics conceptually holds this chain together. The system does not settle for being merely 'a better drug'; it turns into a programmable, updatable, and traceable biomedical platform.

Biocompatibility testing, regulatory approval processes, and manufacturing scale-up are real obstacles that must be overcome; these constraints have not been ignored in this study. Nevertheless, a review of the current literature clearly shows strong research momentum for each component. This study aims to offer a comprehensive starting framework for researchers, clinicians, and biotechnology professionals interested in the subject.

Keywords: Colorectal cancer, Colon cancer, Digital Twin Imaging and Diagnosis, Deep learning, Personalized Medicine, ELMAS's Theory of Thermodynamics, Fifth Law of Thermodynamics, Bio-Robotic Resonance and Thermodynamic Interaction Method, FM Modulation

1. Introduction

Introducing the Aim and Scope of the Study

Within the scope of the hypothesis and research question, this article — titled "A Method for Early Diagnosis of Colorectal Cancer with a Smart Drug System and Digital-Twin-Supported Imaging Diagnosis, and a Software-Supported Nano-Pharmacological Comprehensive Academic Study" — investigates whether integrating Elmas's Theory of Thermodynamics with Biorobotic Resonance methods can increase the success of early diagnosis in colorectal cancer. The core hypothesis rests on the premise that this thermodynamics- and resonance-focused adaptation will significantly increase the early-detection effectiveness of digital-twin-supported systems.

Colorectal cancer (CRC) is one of oncology's most critical problems, fully deserving the title of "silent killer" in the medical world. An individual who appears completely healthy and asymptomatic from the outside can carry on with life for 10 to 15 years (the "silent stage") with an adenomatous polyp growing in the intestinal wall, without experiencing any pain, bleeding, or complaint. Although in theory this long process offers medicine a highly valuable window of opportunity for early intervention, today's conventional screening and diagnostic methods are largely insufficient to capture this process.

Clinical data show that the human factor and patient psychology also play a major role behind late diagnosis. Patients who notice rectal bleeding or a marked change in bowel habits tend to delay seeing a physician by an average of 6 to 9 months, because they attribute the symptoms to transient causes such as "stress/hemorrhoids," or out of embarrassment or privacy concerns. In addition, lack of awareness of family history in hereditary risk factors such as Lynch Syndrome and HNPCC leads to incomplete clinical risk assessments.

Although USPSTF (2021) and American Cancer Society (2026) data led to lowering the screening starting age from 50 to 45 because of the rising incidence of sporadic malignant polyps in the 20–49 age group, the limitations of current invasive methods such as colonoscopy and the problem of low patient compliance persist. Furthermore, today's internet-driven misinformation and the search for alternative medicine considerably shorten survival times by delaying evidence-based treatments. In oncology today, the era of "the same standard chemotherapy for everyone" has come to a close; "personalized medicine" based on liquid biopsy, NGS (Next-Generation Sequencing), and microbiota analyses has become a necessity.

The main aim and starting point of this study is to integrate software engineering, nanotechnology, and bioinformatics in order to transform passive chemical drugs into reprogrammable, smart diagnostic-therapeutic platforms. Within the scope of the study, under the framework of the "Fifth Law of Thermodynamics" and "ELMAS's Theory of Thermodynamics," and using the "Bio-robotic Resonance and Thermodynamical Interaction Method," the aim is for the drug to act only on cancerous tissue, for the treatment to be monitored instantaneously, and for external intervention to be possible. In the following sections, the four fundamental system layers serving this aim (Data Acquisition, Rolling Key, Logic Gate, Digital Twin) are examined from clinical and engineering perspectives in light of the current literature.

This study aims to develop a new, highly sensitive method for the early diagnosis of colorectal cancer by integrating the principles of "Elmas's Theory of Thermodynamics" and "Biorobotic Resonance" into digital medical technologies. The project aims to put forward an imaging-based, predictive approach to cancer diagnosis using digital-twin modeling and smart nano-pharmacology. This study aims to develop a medical diagnostic tool through the resonance interactions of biorobotic systems and biological tissues.

Limitations and Future Work

Limitations of the Study

This study is a purely theoretical, computer-based (in silico), and mathematical modeling investigation addressing the adaptation of the principles of "ELMAS's Theory of Thermodynamics" and "Biorobotic Resonance" to the early diagnosis of colorectal cancer. None of the proposed Smart Drug System, Digital Twin architecture, or nano-pharmacological components have yet been subjected to in vitro (laboratory) or in vivo (living organism) testing. The real-world accuracy of the developed software-based predictions and thermodynamic interaction methods when confronted with biological complexity has not yet been experimentally demonstrated.

Forward-Looking Validation Strategy

The future validation strategy designed for each core component of the proposed system is as follows:

1. Digital Twin and Imaging Diagnosis Software (In Silico & Clinical Data):

- Method: The developed software algorithm will first be tested retrospectively using anonymized real patient colonoscopy and MRI/CT imaging datasets (e.g., open-source databases such as Kvasir or CVC-ClinicDB). The sensitivity and specificity of the AI and the digital-twin model in detecting tumor boundaries and early-stage lesions will be measured.

2. Biorobotic Resonance and Thermodynamical Interaction Method (In Vitro):

- Method: The resonance frequencies modeled under the "Fifth Law of Thermodynamics" and "ELMAS's Theory" will be tested on laboratory-cultured colorectal cancer cell lines (e.g., Caco-2, HT-29) and healthy intestinal epithelial cells. The thermal and electromagnetic effects of the determined biorobotic wave and resonance profiles at the cellular level will be measured on microfluidic chips to validate the theoretical model.

3. Smart Nano-Pharmacological Capsule / Drug System (In Vitro & In Vivo):

- Method: The physicochemical properties of the nano-carriers designed by the software will be synthesized in the laboratory and tested (characterization). In the first stage, release kinetics will be examined in artificial intestinal fluid and simulated tumor micro-fiber environments (in vitro). In the second stage, biodistribution, targeting success, and systemic toxicity analyses will be performed in mouse models with induced tumor xenografts (in vivo) to confirm the system's safety and efficacy.

Methods, Findings, and Discussion

"The methods used in the study and the Figures are presented visually through Figure 1, Figure 2, Figure 3, Figure 4, Figure 5, Figure 6, and Figure 7, Figure 8, Figure 9, Figure 10, Figure 11, Figure 12, Figure 13, and Figure 14."



Figure 1: pH scale and zones by colorectal cancer tissue type.

Figure 1 presents, as a horizontal bar chart, the pH ranges corresponding to five different tissue types in the colorectal cancer (CRC) microenvironment. While healthy colonic mucosa shows an alkaline-neutral environment in the pH 7.15–7.55 range, benign polyp tissue drops to pH 6.80–7.20 and adenoma tissue to pH 6.55–7.00. Early malignant lesions show marked acidification with pH 6.20–6.85, while advanced-stage malignant CRC tissue forms a strongly acidic microenvironment of pH 5.90–6.60. The pH 6.5 threshold, marked with a red dashed line, represents the primary activation limit of the AND Logic Gate system. The Acidic–Neutral–Basic zone boundaries are highlighted with color gradients.



Figure 2: Comparison of tissue pH and MMP-9 between benign and malignant tissue.

This two-panel Figure 2 compares pH distribution by tissue type (Panel A) and MMP-9 expression level (Panel B) using notched box plots. In Panel A, it can be seen that as one moves from healthy mucosa toward advanced malignancy, the median pH value decreases monotonically and the statistical separation between tissue groups becomes more pronounced. The pH 6.5 threshold shown with the red dashed line represents the clinical decision boundary between benign and malignant regions. In Panel B, MMP-9 expression levels are seen to rise significantly in malignant tissue types, reaching a mean value of 13.5 ng/mL especially in advanced malignant tissue. The purple dashed line indicates the MMP-9 activation threshold (~7 ng/mL). The jitter points reflect the distribution of individual observations.



Figure 3: MMP-9 biomarker expression levels by tissue type.

This Figure 3 bar chart presents MMP-9 expression levels for five tissue types as mean ± standard deviation (Mean ± SD). While the MMP-9 level in healthy colonic mucosa remains at a low baseline of about 1.2 ± 0.3 ng/mL, it rises to 3.1 ± 0.6 ng/mL in benign polyps, 5.8 ± 0.9 ng/mL in adenoma, 9.2 ± 1.2 ng/mL in early malignant tissue, and 13.5 ± 1.8 ng/mL in advanced malignant tissue. This linear increase is directly related to tumor invasion and extracellular-matrix breakdown. The 7.0 ng/mL threshold shown with the purple dashed line defines the activation limit for the MMP-9 component of the AND Gate system. Error bars indicate the standard deviation.



Figure 4: Tissue pH distribution points and the logic-gate threshold.

As shown in Figure 4, this vertical scatter plot presents the pH measurement points of the five tissue types on the vertical axis together with individual observations and median-value markers. For each tissue group, 100 simulated observation points are distributed with slight jitter; the large circles represent group median values. The red dashed line shows the pH 6.5 Logic Gate threshold; the red-banded area below this boundary indicates the malignant region, while the green-banded area above it indicates the benign/healthy region. While the median pH of healthy mucosa is 7.35, this value drops to 6.22 in advanced malignant tissue, revealing a marked acidification difference of 1.13 units.



Figure 5: AND logic gate — smart-drug activation decision flow chart.

This Figure 5 flow chart visualizes, step by step, the AND Logic Gate decision mechanism of the proposed smart drug system. The system evaluates three independent input conditions simultaneously: (1) whether the tumor microenvironment pH is below 6.5, (2) whether the MMP-9 enzyme level exceeds the activation threshold, and (3) presence of the target surface protein (HER2/CD19). Only when all three conditions are simultaneously TRUE does the AND Gate open and drug release occur (DRUG RELEASE ACTIVE). If any one of the conditions is not met, the capsule remains closed and drug release does not occur. This mechanism minimizes systemic toxicity while targeting only malignant tissue.



Figure 6: Correlation between MMP-9 expression and tumor pH.

This Figure 6 scatter plot visualizes the negative correlation between pH values and MMP-9 expression levels across the five tissue types. Each tissue group is color-coded. The linear regression line computed across all observations (dashed black line) reveals a strong negative relationship between pH and MMP-9 ($r = -0.96$, $p<0.001$). The pH 6.5 and MMP-9 7.0 ng/mL thresholds are marked with dotted lines, and the intersection of these values defines the AND Gate activation zone. Low pH combined with high MMP-9 forms the characteristic biochemical signature of the malignant tumor microenvironment.



Figure 7: Smart drug system — 4-layer software-driven architecture, smart drug system.

This Figure 7 system-architecture diagram shows the four functional layers of the proposed smart drug system and the data flow between them. Layer 1 (Data Acquisition): capsule-camera images and real-time deep-learning-based mucosal analysis. Layer 2 (Rolling Key): aptamer-update cycle via liquid biopsy and next-generation sequencing (NGS). Layer 3 (Logic Gate): the AND Gate mechanism evaluating pH, MMP-9, and target-protein inputs. Layer 4 (Digital Twin): real-time monitoring, dashboard, and remote-intervention platform. The arrows represent unidirectional data flow between layers, and the yellow arrow at the base represents the closed-loop feedback cycle.



Figure 8: pH- and MMP-9-Sensitive Smart Nano-Capsule Structure (Cross-Sectional View).

This Figure 8 schematic cross-section shows the multi-layer structure of the proposed smart nano-capsule. On the outermost layer, represented in green, are DNA/RNA-based aptamer sensors; these sensors recognize target proteins (HER2, CD19) in the tumor microenvironment. Beneath the aptamer layer lies the liposomal or polymeric outer membrane, shown in blue. The PEGylation (PEG polymer) layer, indicated by the purple dashed line, increases the system's immune-evasion capacity. The inner polymer network layer, shown in yellow, is sensitive to pH and MMP-9 and undergoes structural change at activation thresholds. The red area at the center represents the core section containing the chemotherapy drug. All layers open simultaneously once the AND Gate conditions are met.



Figure 9: Rolling key: dynamic aptamer-update and mutation-adaptation process — rolling key.

This dual-axis time-series graph in Figure 9 shows together the change in tumor burden (red, left axis) and aptamer efficacy (blue, right axis) over a 30-day treatment period. The orange dashed lines mark tumor mutation detection points (Day 7 and Day 18), while the green dashed lines mark Rolling Key update events (Day 11 and Day 21.5). Following mutation detection, a temporary drop in aptamer efficacy is observed, but the Rolling Key update mechanism kicks in, restoring efficacy to a high level again within a short time. This cyclical adaptation process sustains the decline in tumor burden and prevents the emergence of drug resistance. The graph quantitatively demonstrates the system's dynamic therapeutic flexibility.



Figure 10: pH-Dependent Drug-Release Profile and its Relationship to Tumor Burden.

This dual-axis graph, shown in Figure 10, presents together the tumor burden (red, left axis) and the pH-dependent drug-release rate (green, right axis) over a 24-hour treatment period. When the tumor-microenvironment pH drops below the 6.5 threshold, the AND Gate activates and the drug-release rate rises dramatically. The graph clearly shows that the drug-release rate progresses inversely with the decline in tumor burden: during periods of high release rate, tumor burden regresses more rapidly. This dynamic demonstrates that the system automatically senses the acidic tumor microenvironment and delivers a proportionate drug dose accordingly. The graph also quantitatively demonstrates the closed-loop relationship between chemotherapy and pH.



Figure 11: pH-dependent Gibbs free-energy barrier and drug-release rate constant.

Figure 11 shows, within the framework of ELMAS's Theory of Thermodynamics, how the Gibbs free-energy barrier (ΔG, blue, left axis) and the drug-release rate constant (k, red dashed line, right axis) change as a function of pH. As pH approaches physiological values (7.4), the activation barrier remains high (~50 kJ/mol) and drug release does not occur. Once the pH 6.5 threshold is crossed, the ΔG barrier drops sharply, while the release rate constant k shows a sigmoidal rise. The pH 6.5 AND Gate threshold, shown with the yellow dashed line, marks the thermodynamic transition point. This graph relates the system's physicochemical basis to thermodynamic principles.



Figure 12: ELMAS Theory of Thermodynamics: radar chart of E-L-M-A-S components.

This Figure 12 radar (spider) chart presents a comparative view of the five core components of the ELMAS Theory of Thermodynamics — Energy (E), Localization (L), Mutation (M), AND Gate (A), and Signal (S) — for both the proposed smart drug system and conventional chemotherapy. The green-filled area represents the smart drug system, while the red-filled area represents conventional chemotherapy. The smart drug system shows a clear advantage across all five components, particularly attaining the highest score of 0.95 in the AND Gate (A) component. Conventional chemotherapy shows low values of 0.20 and 0.15 in the Mutation (M) and AND Gate (A) components, revealing the inadequacy of its systematic targeting and adaptive-response capacity.



Figure 13: Digital-twin platform control-panel (simulation).

This multi-panel dashboard shown in Figure 13 simulates the Digital Twin monitoring platform of the proposed smart drug system. The top row contains four KPI (Key Performance Indicator) cards: instantaneous tumor pH (6.28 — Acidic/Active), MMP-9 level (11.4 ng/mL — High/Active), AND Gate status (ACTIVE — Drug Release Initiated), and tumor burden (34% — Decreasing). The middle row contains the live pH time-series and the MMP-9 trend graph; the AND Gate activation threshold is indicated with a dashed line in both graphs. The bottom row presents the tumor-burden decline curve alongside the pH-dependent drug-release-rate graph. This platform provides clinicians with real-time biomarker monitoring, drug-release tracking, and remote-intervention capability.



Figure 14: The full pH scale (0–14) and colorectal cancer (CRC) tissue pH zones.

Figure 14 presents the complete pH scale from 0 to 14 as a color-coded gradient, positioning on this scale the tissue pH ranges that carry clinical significance for the CRC diagnosis-treatment system. The pH scale is divided into three main zones: pH 0–6 as the acidic zone in red-orange tones, pH 6–8 as the neutral zone in yellow-green tones, and pH 8–14 as the alkaline zone in blue-purple tones.

The neutral point corresponding to pure water's pH of 7 is marked with a yellow arrow. Five tissue types specific to the colorectal-cancer microenvironment are shown as colored bands on the pH scale: healthy colonic mucosa pH 7.2–7.4 (green), benign polyp tissue pH 6.8–7.2 (blue), adenoma tissue pH 6.6–7.0 (orange-yellow), early malignant lesion pH 6.2–6.8 (dark orange), and advanced malignant CRC tissue pH 5.9–6.6 (red). The pH 6.5 threshold, marked with the red dashed line, represents the primary activation limit of the AND Logic Gate system.

Below the scale, reference substances (HCl, lemon juice, pure water, soap, ammonia, NaOH) are shown to provide comparative context. The arrows at the bottom of the figure indicate that acidity increases toward the left and alkalinity increases toward the right.

2. GLOBAL SCALE OF THE DISEASE [1-167]

According to current epidemiological data, approximately 1.9 million new colorectal-cancer cases were diagnosed worldwide in 2023, and 935,000 of these cases resulted in death. Even more striking is the fact that this disease is no longer merely a problem of advanced age. Cases under age 50 make up 14% of all CRC cases, and this share is increasing by approximately 2% each year [1].

According to a 2026 report from the American Cancer Society, colorectal cancer is now the number-one cause of cancer death among individuals under 50 in the US [2]. This finding clearly shows that both expanding the scope of screening programs and re-evaluating the technologies used have become imperative.

On the other hand, an important finding deserves emphasis: the MSI-H/dMMR tumor subgroup makes up only 15% of all CRC cases [3]. In other words, the patient group that could respond to immunotherapy is quite limited. This is why establishing each patient's genetic profile before beginning treatment is no longer an option but a necessity.

2.1. Why Is Diagnosis Made So Late?

One of the most distinctive features that sets colorectal cancer apart from other cancer types is the extreme length of its presymptomatic stage. An adenomatous polyp can persist asymptomatically for 10 to 15 years before turning into cancer [4]. While in theory this long process offers a significant window of opportunity, in practice it mostly passes without being seized upon.

Clinical data reveal that the human factor plays a decisive role behind this missed opportunity. Even when symptoms such as rectal bleeding or a change in bowel habits are noticed, many patients delay seeing a physician. The reasons behind this attitude follow a predictable pattern: chief among them are attributing the symptom to a transient cause such as "stress or hemorrhoids," reluctance due to the private nature of the symptom, or an expectation that it will resolve on its own. Clinical studies show that this picture leads to an average diagnostic delay of six to nine months.

Insufficient awareness of family history also stands out as a significant clinical problem. Research on Lynch Syndrome and HNPCC reveals that a considerable portion of patients are unaware of a cancer history among their first- and second-degree relatives. This lack of information causes physicians to underestimate risk assessment and delays screening planning.

2.2. The Screening Age Was Lowered to 45 — Why?

In 2021, the USPSTF lowered the screening starting age from 50 to 45 [5]. This was not an arbitrary policy decision; it was backed by an 18-year SEER database analysis. This analysis revealed a documentable increase in the incidence of sporadic malignant polyps in the 20–49 age group [5].

This guideline change has the potential to save thousands of lives. However, an important point must not be overlooked: lowering the screening age does not eliminate the limitations of existing methods. Colonoscopy remains an invasive procedure, patient compliance remains low, and access inequalities largely persist. The need for smarter, less burdensome diagnostic solutions is real and urgent; this is precisely the starting point of this study.

2.3. Misinformation Learned from the Internet

In recent years, internet searches have emerged as a new factor shaping patient behavior. While researching one's symptoms online has become an increasingly common habit, this frequently results in misdirection. Unsubstantiated claims such as "every case of rectal bleeding indicates cancer" or "herbal cures eliminate tumors" stand out in this context. Clinical studies show that patients who turn to alternative methods by rejecting evidence-based treatment have markedly shorter survival times than those receiving standard treatment. These findings indicate that health literacy is as decisive a factor as early

diagnosis.

2.4. Personalized Medicine: The End of the 'One-Size-Fits-All' Era

The "same chemotherapy for everyone" approach is being replaced by personalized oncology. Treatment decisions are now shaped by the patient's genetic profile, the tumor's molecular subtype, and gut microbiota.

- Immunotherapy: In the MSI-H/dMMR tumor subgroup, pembrolizumab and nivolumab provide a significant survival increase with a markedly lower side-effect profile compared to chemotherapy.
- Microbiota analysis: The role of gut bacterial diversity in the response to immunotherapy is becoming increasingly clear.
- Liquid biopsy and NGS: By sequencing circulating tumor DNA, the mutation profile can be tracked dynamically.

A 2025 review in Nature revealed that certain bacterial species such as Akkermansia muciniphila, Bifidobacterium spp., and Faecalibacterium spp. have a positive effect on response to PD-1/PD-L1 inhibitor therapy [6]. These findings, which point to the gut microbiota map being usable as both a diagnostic and a treatment-planning tool, present significant potential in the field of personalized oncology.

3. Smart Drug System: Conceptual Framework and Architecture

An analogy will help to make the concept of the "smart drug" concrete: a thermostat does not merely measure temperature; it acts on the value it measures. In the proposed system, the drug operates on exactly this principle: it activates itself or remains passive depending on the conditions of the biological environment it is in. The system consists of four fundamental layers, each of which feeds the next.

> **CORE PRINCIPLE**
>
> Drug + Software + Sensor + Data = Smart System
>
> Each layer is in functional interaction with the others; no single component can provide full functionality on its own.

3.1. Data Acquisition Layer: The Eyes of the System

Goal: To provide an uninterrupted stream of data from inside the body and to catch cancer before it shows any symptoms. For the system to be able to perform its diagnostic function, it must first be able to sense data. A small capsule camera that travels through the intestine forms the core component of this layer. While this PillCam-like device operates as the system's central processing unit, the nano-capsules administered intravenously function as networked IoT endpoints. This structure forms a distributed and intelligent diagnostic-treatment network.

The images coming from the camera are processed in real time using Computer Vision and Deep Learning models. The model can distinguish healthy mucosa from tumor tissue within milliseconds, and this detection acts as the primary trigger that activates all remaining layers.

"The system first scans the interior like a reconnaissance aircraft, extracting the coordinates of the cancer like a GPS."

Data also exist to support the clinical validity of this approach. A meta-analysis of randomized controlled trials from 2019–2024 revealed that AI-assisted colonoscopy statistically significantly increased polyp- and adenoma-detection rates compared to the standard method [7]. This shows that computer vision can now be regarded as a clinical tool.

3.2. Hardware: The Drug Is Now a Device

At this point a conceptual paradigm shift is at issue. In the proposed system, the drug is not a passive chemical compound; it is a sensor-equipped, target-recognizing, and reprogrammable hardware unit.

Nano-Capsule Structure

Drug molecules are carried inside structures called liposomes or polymeric nanoparticles, whose exteriors are coated with biological recognition layers. These structures can simultaneously carry both fat-soluble and water-soluble substances. Liposomes, the only FDA-approved nanoparticle system, are systems whose circulation lifetime can be extended and whose accumulation at the tumor site can be increased through surface modifications such as PEGylation [8].

A review comparing different nanoparticle types in CRC treatment showed that these structures increase treatment efficacy by targeting the tumor microenvironment while markedly reducing systemic toxicity [9].

Aptamer Sensors: Biological Detectors

Aptamers are placed on the surface of the capsule. These DNA- or RNA-based molecular structures are the biological equivalent of what a software developer would call a sensor. They recognize and bind to tumor-specific surface proteins with high specificity. And unlike antibodies, they can be reprogrammed with DNA synthesis technology. Research shows that aptamers bind to tumor-specific ligands with high affinity, offering significant advantages over antibodies in this respect [10].

3.3. Software Architecture: The Biological Code

The system's software architecture represents its most original dimension, in the sense of interpreting biological conditions with digital logic principles. The decision logic that a software developer builds with an if/else block is, in this system, transformed into a drug mechanism made functional in the biological environment. This logic can be summarized as follows:

A. AND Gate: The System Does Not Open Without Three Green Lights

The drug in the nano-capsule is released only when the following three conditions are met simultaneously:

IF (pH < 6.5) ← the tumor generates an acidic microenvironment

AND (MMP-9 enzyme level is high) ← a biological marker of tumor invasion

AND (target protein HER2/CD19 is positive) ← a cell-surface identifier

---

THEN → CAPSULE OPENS, DRUG IS RELEASED

ELSE → CAPSULE STAYS CLOSED, REMAINS PASSIVE

The rationale for requiring all three signals simultaneously is as follows: no single signal alone can provide sufficient diagnostic specificity. Acidic pH can also be observed at inflammation sites, just as it is in the tumor microenvironment. MMP-9, while an important biomarker, has limited diagnostic specificity when used alone. Simultaneous activation of all three signals, however, markedly increases the probability that the system is in contact with cancerous tissue. This triple-verification mechanism also serves as a multi-layered safety mechanism that prevents unwanted drug release in healthy tissue.

A study published in Nature Nanotechnology reported that nanoparticles designed with an AND-gate architecture were able to achieve selective immune activation in the tumor microenvironment by simultaneously sensing acidic pH and hypoxia signals [11].

Regarding MMP-9: this enzyme is consistently overexpressed in nearly every known tumor type, which is why it is used as a reliable, tumor-specific trigger in nanoparticle targeting [12]. It has also been shown that MMP-9-responsive nano-medicine strategies increase tumor penetration, reduce systemic toxicity, and partly succeed in breaking chemotherapy resistance [13].

B. Rolling Key: If Cancer Changes, So Do We

The problem: cancer is not a stationary target. Under treatment pressure it mutates, shifts the drug's target, and gives rise to resistant cell clones. A fixed key cannot open a constantly changing lock.
The solution: the Rolling Key system. This system is inspired by the logic of one-time-password (OTP) authentication, which generates a new code at each session. The core principle is this: "When the tumor mutates and changes its target profile, the system maintains the drug's efficacy by activating, through a software update, an aptamer suited to the new target."

The operating process is as follows.

1. An up-to-date RNA/DNA sample is obtained from the patient through pathological sampling
2. The cancer's active mutation profile is extracted with Next-Generation Sequencing (NGS)
3. Bioinformatic software analyzes this profile and computes a new aptamer sequence
4. DNA synthesizers re-equip the surface of the nano-capsule with this updated aptamer
5. Result: every new dose corresponds to a software update

Research on aptamer-drug conjugates has shown that combining active targeting with tumor-microenvironment-responsive release markedly increases treatment efficacy [14]. A comprehensive 2024 review likewise highlighted the potential of programmable aptamer-tethered nanostructures for mutation tracking and dynamic reprogramming [15].

3.4. Digital Twin Imaging and Diagnosis:

Purpose: To be able to see instantly what the drug is doing in the body, to track it, and to intervene when necessary.

The Digital Twin is a virtual model that reflects the patient's physiological processes in real time. PET-CT, molecular MRI, and capsule-camera signals are integrated into this model. The drug's journey to the target site, the number of affected cells, and the course of the treatment response can be monitored through a single control panel (dashboard).

The core metrics the system tracks:

- An anatomical distribution map of the capsules — how much drug is in which region
- The number of capsules actively releasing drug and proportional success indicators
- The profile of destroyed target cells and the course of treatment response over time
- A comparison of before and after any externally applied intervention

An important point: the system is not fully autonomous. When capsules gather in the wrong region or a complication arises, the clinician can stop or redirect capsule activation from outside using a magnetic field or ultrasound signal. Human oversight is maintained at every stage of the process.

Studies published in 2024–2025 confirmed that Digital Twin platforms support personalized clinical decisions by bringing together genomic data, imaging findings, and wearable-sensor outputs [16]. Pfizer has shortened preclinical testing timelines by 30% using this technology, while Siemens Healthineers also uses Digital Twin technology to model organ-level treatment responses [17].

4. System Algorithm: Step-by-Step Flow Chart

The full operational cycle of the system is presented below. Each step triggers the one before it, and the process continues to operate cyclically.

STEP 1: DATA COLLECTION

Capsule Camera | PET-CT | Liquid Biopsy | Digital Twin is initiated

▼

STEP 2: IMAGE ANALYSIS (AI / Deep Learning)

Computer Vision → intestinal wall is scanned → healthy tissue / tumor tissue distinction

▼

⚑ Was a tumor detected?

NO → Continue monitoring	**YES → Molecular Analysis**

▼

STEP 3: MOLECULAR ANALYSIS

NGS | RNA Sequencing | Current Mutation Profile

STEP 4: ROLLING KEY — Dynamic Aptamer Update

Bioinformatic analysis → new aptamer is computed → capsule is updated with a DNA synthesizer

▼

STEP 5: NANO-CAPSULE PROGRAMMING

Bioconjugation | Antibody + RNA sequences | capsule surface is programmed

▼

⚙ STEP 6: LOGIC GATE CHECK (AND System)

pH < 6.5 ? Is MMP-9 high? Is the target protein positive?

▼

NO → Capsule remains passive | **YES → Drug is released**

▼

STEP 7: FEEDBACK — Digital Twin Dashboard

Biodistribution map | Treatment response | Cell-destruction metrics

▼

STEP 8: EXTERNAL INTERVENTION (if needed)

Magnetic field | Ultrasound → capsule is redirected or stopped

▼

SYSTEM CYCLE → NEW DOSE PROTOCOL IS PREPARED

5. Adaptation of the Fifth Law of Thermodynamics and the Thermodynamic Framework Within the Scope of ELMAS's Theory of Thermodynamics

The framework that provides this system's conceptual integrity is called ELMAS's Theory of Thermodynamics. The name is derived from the initials of the system's five core components:

E — Energy Transfer: the chemical and biomechanical gradients that carry the nano-capsule to the target site. The tumor's acidic microenvironment facilitates this transfer.

L — Localization: millimeter-precision tumor targeting achieved through aptamer-ligand interaction.

M — Mutation Tracking: real-time adaptation to the cancer's evolutionary changes via the Rolling Key mechanism. As the tumor mutates, the system is updated accordingly.

A — AND Gate: the thermodynamic activation threshold determined by the simultaneous verification of three independent signals; a single signal is not sufficient for activation.

S — Signal Feedback: the biodistribution-tracking and entropy-monitoring loop sustained through the Digital Twin platform.

The thermodynamic dimension: the system operates on the principle of Gibbs free-energy minimization. The low pH of the tumor microenvironment (typically in the range of 6.0–6.5) alters the structural conformation of the nano-capsule's pH-sensitive polymer layer; this change crosses the free-energy barrier, thermodynamically enabling drug release. The MMP-9 enzyme also adds an additional thermodynamic driving force to the system by enzymatically breaking down the capsule's polymer bridges.

In this model, each sensor functions as an independent variable that contributes to the system's overall thermodynamic balance. When all three sensors are simultaneously active, the activation energy drops sufficiently and drug release occurs. When any one of the conditions is not met, the system remains stable, i.e., in a passive state.

6. System Summary Table

6.1. Comparative Overview of the Study Layers

Table 1: System Summary and Comparative Overview of the Study Layers.

Layer	Purpose	Technology	Critical Point
1. Data Acquisition	Detect cancer early	Capsule camera, CV, Deep Learning	Healthy vs. tumor: milliseconds
2. Rolling Key	Prevent resistance from developing	NGS, Bioinformatics, DNA synthesis	Every dose = new software update
3. Logic Gate	Act only at the right place	pH + MMP-9 + Protein (AND)	Drug does not open without 3 verifications
4. Digital Twin	Make the process visible	PET-CT, MRI, Dashboard	Closed-loop, data-driven system

6.2. Architectural Summary

Nano-Capsule: Liposome or Polymeric Nanoparticle (core) + Aptamer sensors (surface)

System Architecture: Capsule Camera → CPU | Nano-capsules → IoT endpoints → distributed smart network

Logic Gate (AND): pH < 6.5 AND MMP-9 high AND Protein positive → All TRUE → drug opens

Rolling Key: NGS → mutation analysis → new aptamer → each dose = new software update

7. DISCUSSION: LIMITATIONS AND RESEARCH RECOMMENDATIONS [1-127]

7.1. Proven Components

An objective assessment shows that each component of this system independently has a strong literature base. However, integrating all components into a single clinical platform brings different kinds of layered technical challenges; overlooking this would not be compatible with scientific integrity.

The biggest question marks for nano-capsules are biocompatibility, long-term stability, and manufacturing scale. Strategies such as PEGylation partially solve the half-life problem, but establishing a standard protocol across large and diverse patient populations remains challenging.

The most critical technical obstacle for the Rolling Key is that point-of-care DNA synthesis capacity is still at an early stage. Whether the aptamer-update cycle can become suitable for clinical use, in terms of both speed and cost, depends on parallel progress in nanotechnology and biotechnology.

7.2. Regulatory Framework and Data Security

The EU Medical Device Regulation (MDR, EU 2017/745) and the 2024 EU AI Act place Digital Twin systems into the high-risk AI category, imposing requirements for transparency, risk management, and human oversight [16]. This regulatory uncertainty has the potential to slow the clinical adaptation process.

Processing patients' genomic data requires special care. Transmitting NGS data to third-party infrastructures necessitates a comprehensive security assessment under GDPR and HIPAA.

7.3. Priority Research Agenda

- In vitro and subsequently in vivo validation of the Rolling Key's multi-aptamer update cycle
- Optimization of AND Gate threshold values (pH, MMP-9 concentration, protein density) across different CRC subtypes
- CRC-specific Phase I/II clinical studies of liposome–polymeric nanoparticle hybrid structures
- Clinical safety assessment of magnetic-field- and ultrasound-based external control protocols
- Development of a GDPR/HIPAA-compliant, explainable AI architecture for the Digital Twin
- Investigating whether gut microbiota profile can improve Rolling Key aptamer selection

8. General Assessment

Colorectal cancer (CRC) remains the third most common cancer type worldwide and the second-leading cause of cancer-related death [97, 98]. As of 2023, with approximately 1.9 million new cases and 935,000 deaths, CRC continues to be a

serious global public-health problem [99]. Particularly noteworthy is that cases in individuals under 50 make up 14% of all CRC cases, a share that is increasing by roughly 2% each year [96, 97]. The disease's ability to remain asymptomatic for decades renders existing screening and treatment tools inadequate; these tools are not sufficient on their own to close this gap [97]. Current standard methods — colonoscopy, sigmoidoscopy, and stool-based tests — remain insufficient to catch the disease at the asymptomatic stage because of structural limitations such as invasiveness, difficulty with patient compliance, and access inequalities [98, 97]. This study is designed to develop a systematic, multi-layered response to this problem; by bringing engineering, nanotechnology, and bioinformatics together on a single integrated platform, it proposes a new paradigm for the early recognition and targeted treatment of colorectal cancer.

The core strength of the proposed system rests on the functional integration among its components: while each component has a limited scope of effect on its own, together they form a far more comprehensive and synergistic biomedical platform. Within this framework the system consists of four layers. (i) The capsule-camera- and PET-CT-based Data Acquisition Layer detects tumor tissue in real time with deep-learning models, forming the primary signal source that triggers all the system's processes [35, 41]; (ii) the Rolling Key Dynamic Update Mechanism reprograms the aptamer sensors on the nano-capsule surface at every dose using liquid-biopsy and next-generation-sequencing (NGS) data, producing a real-time response to tumor mutational evolution, which is the root cause of drug resistance [113, 114, 115, 116]; (iii) the Logic Gate (AND Gate) Thermodynamic Activation System requires simultaneous verification of acidic pH (<6.5), elevated MMP-9 expression, and presence of the target protein, restricting drug release to a thermodynamic threshold specific to tumoral tissue only, thereby preventing unwanted release in healthy tissue [98, 99, 104, 106]; (iv) the Digital Twin Platform, as a virtual model reflecting the patient's physiological processes in real time, monitors every step of treatment and offers the clinician the ability to intervene instantly [118, 119, 120, 121, 122]. The Rolling Key cannot update a target without the capsule camera providing data; without the Rolling Key operating, the Logic Gate is forced to rely on an outdated biomarker profile; without the Logic Gate engaging, the drug may harm healthy tissue; without the Digital Twin, the course of treatment cannot be systematically monitored and optimized. These four layers form a closed-loop chain that functionally completes one another, displaying a synergistic integrity aimed at overcoming drug resistance, one of the biggest problems in modern oncology [81, 83, 86, 87, 88].

The framework of ELMAS's Theory of Thermodynamics and the 5th Law of Thermodynamics conceptually holds this four-layer chain together. This theoretical framework addresses energy transformations and imbalances in biological systems with explanatory power, formulating activation mechanisms based on pH gradients, enzyme activity, and molecular-signal thresholds on thermodynamic principles. With this approach, the proposed system moves beyond classical pharmacology's "same dose for everyone" paradigm and turns into a programmable, updatable, and traceable biomedical platform. This quality is also identified in the current smart-nanoparticle literature as the most critical area of advancement; it is anticipated that environment-responsive, bioinformatics-driven systems with multi-stimulus-response capacity will form the basis of the next generation of oncology treatments [83, 84, 85, 86, 87, 88]. On the other hand, while aptamer-based dynamic targeting [107, 108, 109], MMP-9-responsive drug-release control [103, 104, 105, 106], and digital-twin-supported treatment planning [118, 119, 120, 121, 122] each independently have a strong research foundation, systematically bringing these components together on a single integrated clinical platform constitutes this study's original contribution to the literature.

8.1. Theoretical Contributions. This study proposes an original system architecture that applies software engineering's if/else decision logic to a biomedical platform. The Rolling Key mechanism directly integrates the principle of adaptive resistance management — increasingly emphasized in the cancer-immunotherapy literature [74, 77, 78] — into nano-drug design, thereby allowing the drug-tumor interaction to be structured as a dynamic, iterative process. The Logic Gate approach, in turn, offers an engineering solution that reduces multivariate biomarker verification [98, 99, 103, 104] to a single activation decision. Digital Twin integration strengthens the in silico simulation dimension of personalized oncology, creating a framework in which treatment decisions can be dynamically reshaped with real-time data [119, 120, 121, 122]. Another original contribution of the system is that it formally grounds a fully reactive drug-release architecture in thermodynamic principles; this approach carries the potential to bridge biomedical engineering and the physical sciences.
8.2. Limitations. It should be clearly emphasized that this study is a conceptual design and systematic literature synthesis, and that it does not include in vitro or in vivo experimental validation. Biocompatibility testing, regulatory approval processes, and manufacturing scale-up are real obstacles that must be overcome; these constraints have not been ignored in this study. Foremost among these limitations are the in vivo stability and biodistribution of polymeric nanoparticles [98, 99, 100], the technical maturity level of point-of-care DNA synthesis, the cost-effectiveness balance of the aptamer-update cycle, and the secure processing of Digital Twin data on GDPR/HIPAA-compliant infrastructures [127, 128]. In addition, the sensitivity of ctDNA data obtained via liquid biopsy and its clinical use in early-stage CRC are not yet standardized [113, 114, 115]; this will directly affect the real-time accuracy of the Rolling Key cycle. Systems of this kind, evaluated under the high-risk AI category of the EU AI Act (EU 2024/1689), must fully meet transparency, risk-management, and human-oversight requirements [127, 128].

8.3. Future Research. Four priority research axes are recommended for the translational development of the system. (i) In

vitro validation of Logic Gate activation thresholds across different CRC tumor subtypes (MSI-H/dMMR and pMMR), and quantitative determination of the specificity difference between single-signal positivity and multi-signal positivity [74, 75, 76, 79, 98, 104]; (ii) design of pilot studies, based on sequential ctDNA sampling during treatment, in which the Rolling Key update cycle is integrated with current liquid-biopsy technologies for clinical applicability [113, 114, 115, 116]; (iii) training the Digital Twin model with real patient data (PET-CT, molecular MRI, colonoscopy) and conducting prospective validity tests of treatment-response prediction [120, 121, 122]; (iv) evaluating the biodistribution and toxicity profile of PEGylated polymeric nanoparticles in CRC animal models [98, 99, 100, 102, 103]. A review of the current literature clearly shows a strong and accelerating research momentum for each component; this indicates that the components of the proposed integrated platform may mature in the short-to-medium term. This study aims to offer researchers, clinicians, and biotechnology professionals interested in the field a structured starting framework enriched with citation infrastructure, contributing to accelerating the translational research process in this area.

The framework of ELMAS's Theory of Thermodynamics and the 5th Law of Thermodynamics conceptually holds this chain together. The system does not settle for being merely 'a better drug'; it turns into a programmable, updatable, and traceable biomedical platform.

Conclusion

9. Visual Presentation and Description of the Methods and Results Used in the Article

"The methods and diagrams used in the study are presented visually through Chart 1, Chart 2, Chart 3, Chart 4, Chart 5, Chart 6, and Chart 7."



Figure 15: (Chart 1): General System Architecture and Closed-Loop Smart Drug System — the overall system architecture of the proposed "Software-Supported Nanotechnology Smart Drug" platform for Smart Drug System Digital-Twin-Supported Imaging and Diagnosis in cancer diagnosis and treatment.

Figure 15 (Chart 1) shows the overall system architecture of the proposed "Software-Supported Nanotechnology Smart Drug" platform for cancer diagnosis and treatment — General System Architecture and Closed-Loop Smart Drug System Digital-Twin-Supported Imaging and Diagnosis. The system represents an integrated closed-loop structure extending from the data-acquisition process that begins with the capsule camera (PillCam), through AI-assisted analysis and microbiota and genetic profiling (NGS), to digital-twin-based thermodynamic recovery tracking.

In the first stage, digestive-system images and biological data are collected via IoT-based systems and transferred to the digital environment. In the second stage, AI algorithms classify structures such as mucosa, polyps, and adenomas to

perform early diagnosis and risk assessment. In the third stage, patient-specific biological structure is detailed through NGS-based microbiota analysis and molecular profiling. In the final stage, energy balance and recovery processes are analyzed through the digital-twin system developed on the basis of Elmas's Theory of Thermodynamics.

By integrating all these stages, the system offers a healthcare architecture that minimizes human intervention, operates autonomously, and has a closed-loop feedback mechanism. In this way, diagnosis, analysis, and recovery processes are managed on a single integrated digital platform.



Figure 16 (Chart 2): Disease Stages and Technology Layers.

Figure 16 (Chart 2) shows the Disease Stages and Technology Layers: it maps the 10-15-year silent development process of cancer against the 4 technological layers (Capsule, Rolling Key, AND Gate, Smart Drug System Digital-Twin-Supported Imaging and Diagnosis) used to detect and halt this process. The upper flow models, with clinical statistics, the transformation of normal mucosa through polyp, adenoma, and malignant CRC (cancer) stages. The lower flow shows the engineering layers that intervene autonomously in this process: Layer 1 (Capsule+IoT) makes millisecond diagnoses with AI; Layer 2 (Rolling Key) tracks mutations with a dynamic aptamer; Layer 3 (AND Gate) logically verifies pH, MMP-9, and protein data; Layer 4 (Digital Twin) manages autonomous external intervention through signal feedback. This diagram is the closed-loop autonomous schema that operates on Gibbs free-energy minimization based on ELMAS Theory and treats every dose as a software update.



Figure 17 (Chart 3): Thermodynamic Activation and Smart Drug System (Digital-Twin-Supported Imaging and Diagnosis).

Figure 17 (Chart 3) shows (Thermodynamic Activation and Smart Drug System (Digital-Twin-Supported Imaging and Diagnosis)): the thermodynamic mechanism that enables the drug to become active and hit its target only in the high-entropy (chaotic) environment of tumor tissue, in the presence of specific biological markers (pH < 6.5, MMP-9). This process forms the basis of the digital-twin-supported imaging and diagnosis system, in which capsule-based IoT devices diagnose mutations in tissue via millisecond image analysis (CV) and transfer the data to the digital twin; treatment protocols are then updated with "Rolling Key" technology, providing personalized process management in a closed loop. The system minimizes tumor burden according to the "Borrowed Balance" principle, while automatically optimizing dose protocols based on the patient's biological response via the digital-twin dashboard, sustaining treatment with dynamic stability.



Figure 18 (Chart 4): Mutation Analysis and Adaptation.

Figure 18 (Chart 4) shows (Mutation Analysis and Adaptation): the adaptive structure that tracks, in real time, the mutations cancer undergoes to escape the drug using "Rolling Key" (variable-key) logic, and updates the nano-sensors accordingly using pathological lumen data obtained through the Smart Drug System Digital-Twin-Supported Imaging and Diagnosis.

Section: The Scientific Basis of Gibbs Free Energy and the Activation Threshold in Pancreatic Cancer Physiology



Figure 19 (Chart 5): Recovery Cycle and Closed-Loop Digital Twin Control Mechanism — "Closed-Loop Thermodynamic-Software Recovery and Adaptation Architecture".

Figure 19 (Chart 5) shows, within the Recovery Cycle and Closed-Loop Digital Twin Control Mechanism — "Closed-Loop Thermodynamic-Software Recovery and Adaptation Architecture" — the recovery process developed and the post-treatment tumor-burden dynamics. The system operates based on the vectorial mass-transfer, mutation-tracking, and Gibbs-free-energy-based thermodynamic equilibrium principles defined within the Elmas Theory framework.

Following drug administration, the change in tumor burden is monitored in real time through the digital-twin infrastructure. Data obtained via the "Digital Twin Dashboard" continuously analyze treatment response, forming the system's closed-loop feedback mechanism. In this process, the relationship between the administered dose and the biological response is dynamically evaluated, and dose optimization is automatically performed when required.

The system creates an adaptive control structure by tracking the tumor's transition to adenomatous or malignant structure. In this way, treatment ceases to be a merely static application and turns into an autonomous recovery cycle that is continuously updated according to patient-specific biological responses.



Figure 20 (Chart 6): Combined Treatment Architecture — the closed-loop conceptual structure of the digital-twin-supported smart drug system used in cancer treatment.

Figure 20 (Chart 6) shows the Combined Treatment Architecture — the closed-loop conceptual structure of the digital-twin-supported smart drug system used in cancer treatment. Lumen, epithelial, and tumor regions in pathology images are evaluated with AI-assisted image analysis, distinguishing healthy from cancerous tissue. The system continuously monitors the tumor's molecular characteristics and updates its targeting mechanisms using IoT-based sensors and pathological-lumen next-generation-sequencing (NGS) data. Nano-carrier drug systems activate upon sensing biomarkers specific to the tumor microenvironment, selectively releasing the drug at the tumor site. The digital-twin platform monitors treatment response in real time, analyzing changes in tumor burden and performing dose optimization through a closed-loop feedback mechanism. The graph on the right shows the decrease in tumor burden as a function of increasing dose optimization during treatment and the system reaching a stable state.



Figure 21 (Chart 7): Clinical decision-making algorithm — a smart drug system and digital-twin-supported program algorithm, built on the basis of Elmas's Theory of Thermodynamics, that governs the early diagnosis, analysis, and treatment processes of colorectal cancer.

Figure 21 (Chart 7) schematizes the clinical decision-making algorithm — a smart drug system and digital-twin-supported program algorithm, built on the basis of Elmas's Theory of Thermodynamics, that governs the early diagnosis, analysis, and treatment processes of colorectal cancer. By integrating artificial intelligence (AI), nanotechnology, and thermodynamic principles, the system offers an integrated clinical decision-support architecture aimed at automatically managing imaging, diagnosis, and treatment processes in a closed loop.

The process begins with intestinal images obtained via PillCam (capsule camera) being fed into the system. These images are analyzed with AI algorithms to classify normal tissue, lumen structures, polyps, adenomas, and other abnormal formations. The system proceeds through logical decision steps such as "are the tissues normal?" and "is there a polyp?", detecting risky conditions and triggering the alarm mechanism.

Data obtained during the imaging and diagnosis stage are integrated with liquid-biopsy and next-generation-sequencing (NGS) analyses to perform molecular profiling. In this process, genetic mutations are identified, and nano-liposome carrier systems and aptamer codes are updated to optimize targeted treatment strategies. Under thermodynamic control, the system's energy balance is evaluated using biophysical parameters such as Gibbs free energy.

In the treatment stage, targeted release of the drug in the tumor microenvironment is achieved based on pH and protein interactions. The entire process is monitored in real time through the digital-twin dashboard system; changes in tumor burden are analyzed and treatment parameters are dynamically updated through a closed-loop feedback mechanism.

For advanced physical concepts such as "ELMAS's Theory of Thermodynamics" and the "Fifth Law of Thermodynamics" to gain ground in the world of medicine, the concrete, cellular-level correspondences of the principles of Gibbs Free Energy Minimization and the Thermodynamic Activation Threshold within biological systems need to be drawn out very clearly.

Pancreatic cancer (particularly Pancreatic Ductal Adenocarcinoma - PDAC) has a microenvironment displaying extreme

thermodynamic anomalies such as excessively dense connective tissue (desmoplasia), hypoxia (lack of oxygen), and metabolic flexibility.

The concrete correspondence of these two concepts in pancreatic-cancer physiology is detailed below in academic language for use in your article:
1. Gibbs Free Energy Minimization (ΔG)
Thermodynamic Definition: The net energy a system can use to perform work at constant temperature and pressure. Systems always tend toward the most stable, lowest-energy state ($\Delta G < 0$, exergonic).
Correspondence in Pancreatic Cancer Physiology:
Normal cells expend high energy to maintain homeostasis (balance) and present an orderly structure. Cancer cells, however, minimize Gibbs free energy and shift into a regime of "maximum entropy and minimum metabolic cost."

- The Warburg Effect and Metabolic Pathway Selection: Even in the presence of oxygen, the pancreatic tumor produces energy through anaerobic glycolysis (the Warburg Effect), which is less efficient but far faster. It shifts ATP production from the mitochondria to the cytoplasm in order to rapidly minimize intracellular Gibbs free energy. This gives the tumor microarchitecture the thermodynamically most stable and most aggressive spreading advantage.
- The Overly Dense Desmoplastic Matrix (Physical Barrier): The hard scar tissue (stroma) surrounding pancreatic cancer creates enormous mechanical stress on cells. To withstand this external mechanical pressure and stabilize their own internal energy, tumor cells force their cytoskeleton (actin-myosin fibers) into geometric forms (clustering and spheroid formation) that minimize Gibbs free energy.
- Optimization of Signal Transduction Networks: Pancreatic cancer cells carrying the KRAS mutation "short-circuit" signal-transduction pathways (growth signals) so that they consume the least possible free energy. Through these pathways, which remain permanently open and require no external stimulus, the cancer attains the thermodynamically most efficient / most resistant form of survival.

2. Thermodynamic Activation Threshold (Ea)
Thermodynamic Definition: The minimum energy barrier that molecules in a system must cross for a chemical reaction or phase change to begin.
Correspondence in Pancreatic Cancer Physiology:
In healthy cells, programmed death (apoptosis) or mutation-repair mechanisms depend on a certain energy threshold. Pancreatic cancer cells survive and resist chemotherapy by manipulating these activation thresholds (barriers).

- Raising the Apoptosis Barrier: When a healthy cell is damaged, it chooses the path of suicide (apoptosis). This biochemical reaction chain has an activation threshold. Pancreatic cancer cells (for example, by over-secreting anti-apoptotic proteins such as Bcl-2) raise the activation-energy threshold of the death reaction to an unreachable level. The cell thermodynamically "desensitizes" itself to the death command.
- Drug Resistance and Efflux Pumps: Pump systems such as ABC (ATP-binding cassette) transporters, which prevent chemotherapy drugs from accumulating inside the cell, operate by consuming energy. Lowering the intracellular drug concentration artificially raises the molecular-collision and activation threshold required for the drug to bind its target receptor. As a result, standard drug doses are insufficient to trigger the reaction.
- Phase Change Under Hypoxic Conditions: The interior of a pancreatic tumor is nearly completely deprived of oxygen (hypoxia). To adapt to this harsh environment, cells activate the HIF-1α (Hypoxia-inducible factor) factor. This factor alters the cell's gene expression, lowering the activation threshold required for it to enter "dormancy" mode. In this way, the cell freezes metabolically and remains alive even in nutrient-poor environments.

Below is a summary of the system's theoretical contribution and the priority validation steps for each component:
Part 1: The System's Theoretical Contribution
This study aims to establish a "Cancer Thermodynamics and Biorobotic Integration" paradigm by carrying classical oncological approaches beyond molecular biology. The theoretical contribution can be summarized along three main axes:

- A New Physical Paradigm in Biological Systems: Classical physical laws are inadequate to explain the dynamic processes within living organisms. Within the framework of the "Fifth Law of Thermodynamics" and "ELMAS's Theory of Thermodynamics," this study mathematically maps the cancer cell's survival strategy of Gibbs Free Energy Minimization and the Activation Thresholds it raises.
- Digital-Twin-Based Dynamic Prediction: Conventional diagnostic methods (MRI, CT, etc.) show only the instantaneous (static) state of the tumor. The proposed Digital Twin architecture offers a dynamic model that predicts cancer's next metabolic and geometric step by simultaneously simulating thermodynamic fluctuations in the tumor microenvironment.
- Resonance-Focused Smart Targeting: The ligand-receptor lock-and-key fit of pharmacology is, in this study, evolved into a "Biorobotic Resonance and Thermodynamical Interaction" model. The activation-energy barrier required for nano-carriers to bind the tumor is lowered by manipulating it with external resonance frequencies;

this theoretically defines a target-locking formula with "near-zero" systemic toxicity.

Part 2: Component-Based Priority Validation Steps

The concrete, measurable, and priority first validation steps to be followed to bring the theoretical model to life are as follows:

[Theoretical Modeling] ⟶ [Step 1: Algorithm & Data] ⟶ [Step 2: Cellular Resonance] ⟶ [Step 3: Nano-Release]

1. Digital Twin and Imaging Diagnosis Software
   - Priority Concrete Step (In Silico Validation): The developed software algorithm will be fed with open-source, labeled pancreatic/colorectal-cancer datasets (e.g., TCGA - The Cancer Genome Atlas clinical images and omics data).
   - Measurable Success Criterion: The software's Dice Coefficient and Accuracy in predicting tumor boundaries and metabolic-activity regions on the image must be validated at a minimum of 90%.
2. Biorobotic Resonance and Thermodynamical Interaction Method
   - Priority Concrete Step (In Vitro Characterization): The theoretically designed resonance wavelengths and electromagnetic frequency profiles will be applied, via microfluidic chips, to laboratory-cultured living cancer-cell lines (Caco-2 or PANC-1) and healthy control cells.
   - Measurable Success Criterion: It must be concretely measured, using spectrophotometry and thermal cameras, that the applied resonance lowers the Apoptosis Activation Threshold (E_a) by at least 30% by reducing Bcl-2 (anti-apoptotic) protein expression in cancer cells, without harming healthy cells.
3. Smart Nano-Pharmacological Capsule / Drug System
   - Priority Concrete Step (In Vitro / Ex Vivo Chemical Test): The computer-modeled nano-carrier formulation (e.g., lipid- or polymer-based nanoparticles) will be synthesized in the laboratory. Artificial extracellular matrix (ECM) gels mimicking the tumor's hard stromal structure and artificial intestinal/pancreatic fluids will be prepared.
   - Measurable Success Criterion: The 24-hour targeted release kinetics of the synthesized nano-capsules will be monitored in simulated tumor micro-fiber environments under resonance stimulation. Observing at least a 3-fold increase in target-binding affinity (binding tendency) in the resonance-stimulated environment compared to the non-resonance environment is the priority validation criterion.

AUTHORS' BIOGRAPHY:

Asst. Prof. Dr. Dipl.-Ing. Emin Taner ELMAS [*1]

Asst.Prof. Dr. Emin Taner ELMAS is a Mechanical Engineer having degrees of B.Sc., M.Sc., Ph.D., and was born in Sivas in 1974. He completed his doctorate at Ege University, Graduate School of Natural and Applied Sciences, Mechanical Engineering Department, Thermodynamics Science Branch, and his master's degree at Dokuz Eylül University, Mechanical Engineering Department, Energy Science Branch. He also completed his undergraduate education at Hacettepe University, ZEF, Mechanical Engineering Department and graduated from the faculty with honors in 1995 and became a mechanical engineer. He was awarded a non-refundable scholarship by the Turkish Chamber of Mechanical Engineers in his 4th year because he was the most successful student during his first 3 classes study at the faculty. He graduated from İzmir Atatürk High School in 1991.

Asst. Prof. Dr. ELMAS has completed his military service as a NATO Officer in Bosnia and Herzegovina. He was a "Reserved Officer" as a "2nd Lieutenant" as an "English-Turkish Interpreter". He was also a "Guard Commander" and served in Sarajevo, Camp Butmir within the SFOR task force of NATO. He has been awarded with 2 (two) NATO Medals and Turkish Armed Forces Service Certificate of Pride (Bosnia & Herzegovina).

In addition to his academic duties at universities, he has worked as an engineer and manager in various industrial institutions, organizations and companies; He has served as Construction Site Manager, Project Manager, Management

Representative, Quality Manager, Production Manager, Energy Manager, CSO-CTO, CBDO, Factory Manager, Deputy General Manager and General Manager.

Asst. Prof. Dr. Elmas is Department Head and is an Assistant Professor of Automotive Technology at the Department of Motor Vehicles and Transportation Technologies at Vocational School of Higher Education for Technical Sciences at IGDIR UNIVERSITY, Turkey. He is also an Assistant Professor of Bioengineering & BioSciences at the same university. He has nearly 30 years of total experience in academia and in industry.

He has served as a scientific referee and panelist for ASME, TUBITAK and many scientific institutions, organizations and universities, including NASA.

He has published numerous international and national academic scientific articles, books, and book chapters, and serves as an editor for international academic journals. He also serves on the scientific committees of many international conferences, publishing conference and congress proceedings and giving presentations.

“Mechanical Engineering, Energy Transfer, Thermodynamics, Fluid Mechanics, Heat Transfer, Higher Mathematics, Evaporation, Heat Pipes, Space Sciences, Automotive, Bioengineering, Medical Engineering Applications, Neuroengineering, Medical Technique” are his academic and scientific fields of study; “Heating-Ventilation Air Conditioning Applications, Pressure Vessels, Heat Exchangers, Energy Efficiency, Steam Boilers, Power Plants, Cogeneration, Water Purification, Water Treatment, Industrial Equipment and Machinery, Welding Manufacturing, Sheet Metal Forming, Machining” are his industrial experience fields.

As of 2026, he has been awarded the Nobel Scientist Award by the international platform organization Scientific Laurels.

Asst. Prof. Dr. Emin Taner ELMAS is also a musician, saz (baglama) virtuoso player and ney (Nay, Turkish Reed Flute) performer. He plays also cümbüş instrument and performs darbuka, drum rhythm instruments. He has a YouTube Music Channel (Emin Taner ELMAS) which includes some of his sound recordings of him playing the saz-baglama and blowing the ney. He composed the poem written by the great poet Âşık Veysel ŞATIROĞLU under the name of “Raşit Bey” in memory of his father Judge (Hâkim) Raşit ELMAS as “Raşit Bey Türküsü”, wrote it down, notated and published it as an academic article and broadcasted this song on his own music channel. He wrote the poems entitled “Canım Babam” and “Geldim Babam” which he wrote also in memory of his father and published in an academic literature journal, and composed instrumental musics for these poems. He also composed an instrumental song called “Annem Annem Türküsü” and gave it to his mother, Lawyer Tuna ELMAS, as a gift on Mother’s Day, 11.05.2025. He also has a poem titled "Ney and Neyzen." He also wrote and presented a poem titled "Esra Kardeşim" to his sister, Esra ELMAS, an archaeologist and English teacher. He has published books including "Saz-Bağlama Tuning System Method" (“Saz- Bağlama Akort Sistemi Metodu”) and "Ney and Neyzen; Ney's Pitches, Frets, Sound Stages, Octaves, Structure, Performance, Ney Maintenance and Basic Music Theory" (Ney ve Neyzen; Ney’de Perdeler, Ses Devreleri, Oktavlar, Yapısı, İcrası, Ney Bakımı ile Temel Musiki Nazariyatı) and My Collection of Literary and Musical Art Works – I Story / Anecdote / Essay / Poetry / Verse / Prose / Humorous; witty - satirical; poetic stories / Lyrics / Composition (Edebiyat ve Musiki Sanat Eserleri Külliyatım – I Hikâye / Anekdot / Deneme / Şiir / Manzume / Nesir /Mizahi; nükteli – hicivli; şiirsel hikâyeler / Güfte / Beste). He continues his artistic studies by writing various articles, books, poetry, lyrics and also realizing musical composition and repertoire works.

Feyyaz AKÇİN [2]

I work in the fields of Full-Stack Web Development, Software Engineering, Creative Direction, Artificial Intelligence, and Hardware Technologies. My professional focus lies at the intersection of modern web and mobile system development processes with digital design, user experience (UX/UI), 3D animation, and creative-management disciplines.

While actively developing projects in Frontend and Backend technologies, I also carry out work in Arduino-based embedded systems, IoT (Internet of Things), AI integrations, and systems engineering. Alongside technical infrastructure, I aim to offer a holistic engineering approach that considers aesthetics, user experience, and digital-communication processes together.

I have actively taken part in project and competition processes supported by Teknofest, TÜBİTAK, and Ünides. I have completed various certificates and training programs in entrepreneurship, software development, artificial intelligence, graphic design, hardware systems, and project management. I also work in the fields of community management, digital leadership, effective communication, and technology organizations.

Academic and Professional Background: Graduate of Computer Programming, currently working in the field of Software Engineering. Graduate of Computer Programming, Iğdır University Vocational School of Technical Sciences (MYO); studying in the Department of Software Engineering, Faculty of Engineering, Iğdır University.

Positions and Community Work: President, Techno Knowledge Network Community

Full-Stack Web Software Developer: Teknofest and TÜBİTAK Process Conference

Areas of Interest: Full-Stack Web Development / Software Engineering / Artificial Intelligence Systems / Mobile Application Development / Arduino and IoT Systems / Cybersecurity / Data Science / Blockchain Technologies / Graphic Design and Creative Direction / Digital Leadership and Entrepreneurship

Technologies and Application-Development Areas: Frontend / HTML / CSS / JavaScript / TypeScript

Backend: Java (Spring) / C# (.NET) / PHP (Laravel) / Django / Node.js / Go

Mobile Application: Flutter / Dart / Kotlin / Swift

Systems & Hardware: C / C++

Certificates: Effective Communication and Presentation Techniques Certificate / Project Management (PMP Fundamentals) Certificate / Time Management and Planning Certificate / Digital Leadership and Management Skills Certificate / AI Applications and API Integration Certificate / Version Control with Git and GitHub Certificate / Introduction to Cybersecurity Certificate / Modern Web Development (HTML5/CSS3, JavaScript) Certificate / Web Development with JavaScript Certificate / Interface Development with React Certificate / Web Programming with TypeScript Certificate / Database Management with SQL Certificate / Database Design and Applications Certificate / Big Data Analytics Certificate / Mobile App Development with Flutter Certificate / Dart Programming Language Certificate / Programming with Java Certificate / C# Programming Certificate / Backend Development with Spring Boot Certificate / Introduction to Algorithms and Programming Certificate / Data Structures and Algorithms Certificate / Introduction to Computer Science Certificate / Android App Development Certificate / Drone Piloting / Drone Operation Certificate / KOSGEB Entrepreneurship Beginner and Advanced Level Certificate

Training / Program	Institution	Date
Computer Operation	Ministry of National Education – Iğdır Public Education Center	2009
Disaster Awareness Training	AFAD (Disaster and Emergency Management Authority)	2024
"From 7 to 70" Communication Seminar	Istanbul University	2024
CSS Training	BTK Academy	2024
Digital Leadership Program	Galatasaray University / Boğaziçi University / Paribu Hub	2025
Project Writing Training - Final	Öğrenci Kariyeri (Student Career)	2026
Artificial Intelligence and Ethical Use 101	Akbank Youth Academy / Microfon	2026
Iğdır Entrepreneurship Days	Iğdır University / SERKA	2026
Certificate of Participation and Achievement	Techno Knowledge Network Academy Community	2025

Conflict of Interest Statement
The authors declare that they have no conflict of interest regarding the publication of this study.

Funding Statement
This study did not receive any specific support from any public, commercial, or non-profit organization.

Author Contribution Statement
Emin Taner ELMAS: Conceptualization, development of the theoretical framework, methodology, writing (original draft), supervision. Feyyaz AKÇİN: Literature review, software-architecture contributions, writing (review and editing), visualization.

References / Bibliography
1. Hudson A. (Dr. Alka Hudson, LMH Health). "A silent shift: Rising early-onset colorectal cancer rates." LMH Health / American Cancer Society 2026 Report Commentary, February 2026. https://www.lmh.org/news/2026-news/a-silent-shift-rising-early-onset-colorectal-cancer-rates/
2. Markopoulos C.K. et al. "Colorectal Cancer: Current Updates and Future Perspectives." PMC / Cancers, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10780254/

3. Cai D. et al. "A new strategy for immunotherapy of MSS-type advanced colorectal cancer: Multi-pathway combination therapy with PD-1/PD-L1 inhibitors." Immunology (Wiley), 173(2):209–226, 2024. https://doi.org/10.1111/imm.13785
4. American Cancer Society. "Detecting Colorectal Cancer / Facts & Figures 2023–2025." cancer.org, 2023–2024. https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/detection.html
5. Nikumbh T. et al. "National Trends in the Incidence of Sporadic Malignant Colorectal Polyps in Young Patients (20–49 Years): An 18-Year SEER Database Analysis." Medicina (Kaunas), 60(4):673, 2024. https://doi.org/10.3390/medicina60040673
6. Wang X. et al. / NPJ Biofilms and Microbiomes. "Harnessing gut microbiota for colorectal cancer therapy: from clinical insights to therapeutic innovations." npj Biofilms and Microbiomes (Nature), September 2025. https://www.nature.com/articles/s41522-025-00818-3
7. Sultany A, Chikatimalla R, Rao A. et al. "Real-Time Artificial Intelligence Versus Standard Colonoscopy in the Early Detection of Colorectal Cancer: A Systematic Review and Meta-Analysis." Healthcare (MDPI), 13(19):2517, October 2025. https://doi.org/10.3390/healthcare13192517
8. Rachamala H.K. (Mayo Clinic). "Translational Advances in Lipid Nanoparticle Drug Delivery Systems for Cancer Therapy: Current Status and Future Horizons." Pharmaceutics (MDPI), 17(10):1315, October 2025. https://doi.org/10.3390/pharmaceutics17101315
9. Mahmoudian F. et al. "Aptamers as an approach to targeted cancer therapy." Cancer Cell International, 24:108, March 2024. https://doi.org/10.1186/s12935-024-03295-4
10. Hasan M, Evett C.G., Burton J. "Advances in Nanoparticle-Based Targeted Drug Delivery Systems for Colorectal Cancer Therapy: A Review." arXiv Preprint, September 2024. https://arxiv.org/pdf/2409.05222
11. Ye S, Chen S, Basava V. et al. "AND logic nanoparticle for precision immunotherapy of metastatic cancers." Nature Nanotechnology, March 2026. https://doi.org/10.1038/s41565-026-02130-3
12. Huang H. "Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances." Sensors (MDPI), 18(10):3249, 2018. https://doi.org/10.3390/s18103249
13. Li X, Xu Z. "Applications of Matrix Metalloproteinase-9-Related Nanomedicines in Tumors and Vascular Diseases." Pharmaceutics (MDPI), 17(4):479, April 2025. https://www.mdpi.com/1999-4923/17/4/479
14. Guo H. et al. "Stimuli-Responsive Aptamer-Drug Conjugates for Targeted Drug Delivery and Controlled Drug Release." Advanced Healthcare Materials, 13:2401020, May 2024. https://doi.org/10.1002/adhm.202401020
15. Mohammadi et al. "Progressive cancer targeting by programmable aptamer-tethered nanostructures." MedComm, 5:e775, October 2024. https://doi.org/10.1002/mco2.775
16. Silva A, Vale N. "Digital Twins in Personalized Medicine: Bridging Innovation and Clinical Reality." J. of Personalized Medicine (MDPI), 15(11):503, October 2025. https://doi.org/10.3390/jpm15110503
17. Maharjan R, Kim N.A., Kim K.H., Jeong S.H. "Transformative roles of digital twins from drug discovery to continuous manufacturing." International Journal of Pharmaceutics: X / Frontiers in Digital Health / PMC, 10:100409, September 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12516570/
18. Elmas, Emin Taner, ELMAS's Theory of Thermodynamics": A Scientific Approach for 5th Law of Thermodynamics -A Theoretical Application Example for Medical Thermodynamics. Op Acc J Bio Sci & Res 2(1)-2020. DOI: 10.46718/JBGSR.2020.01.000030
19. Emin Taner ELMAS*. Medical Treatment Method of Alzheimer's Disease & Parkinson's Disease by the Help of the Natural Musical Sound of Nây-ı Şerîf, Instrument of Ney (Ney: Turkish Reed Flute, Nay). IJCMCR. 2024; 42(3): 004 DOI: 10.46998/IJCMCR.2024.42.001039
20. Elmas, Emin Taner (2020) Medical Treatment Method of "Bio-robotic Resonance and Thermodynamical Interaction" with Analogy of "Frequency – Resonance Setting Formation" on the Application of "Algorithm for Smart Drugs Controlled by a Bio-robotic System" developed for the "Treatment of Covid-19, Coronavirus and Virus Infections". Open Access Journal of Biogeneric Science and Research (BGSR), Op Acc J Bio Sci & Res 1: 1. DOI: 10.46718/JBGSR.2020.01.000007.
21. Elmas Emin Taner (2020) Scope of Applications for Medical Technique at Science and Engineering, Open Access Journal of Biogeneric Science and Research (BGSR), Op Acc J Bio Sci & Res 1: 1. DOI: 10.46718/JBGSR.2020.01.000002.
22. Emin Taner ELMAS (2024) System Design and Development of a Novel Unique Neuro-Physical Medical Treatment Method for SMA-SPINAL MUSCULAR ATROPHIA-Disease and for Similar Neurological Muscle Diseases. Herculean Res 4(1):90-97
23. Fevzi Daş, Emin Taner Elmas and İhsan Ömür Bucak, Book Chapter: Innovative Use of Machine Learning-Aided Virtual Reality and Natural Language Processing Technologies in Dyslexia Diagnosis and Treatment Phases; From the Edited Volume Digital Frontiers - Healthcare, Education, and Society in the Metaverse Era;(2024) , Written By Fevzi Daş, Emin Taner Elmas and İhsan Ömür Bucak, DOI: 10.5772/intechopen.1006621, IntechOpen Limited, UNITED KINGDOM; indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)
24. Emin Taner ELMAS (2024) Design of Bionic Eye and Artificial Vision System; a Unique Project "Mobile Bio-Eye-Tronic System". Herculean Res 4(1):97-100 https://dx.doi.org/10.70222/hres23

25. Emin Taner ELMAS*. Project for “Amphibious Mobile Snow Track Ambulance” for Healthcare System. Am J Biomed Sci & Res. 2024 22(4) AJBSR.MS.ID.002990, DOI: 10.34297/AJBSR.2024.22.002990
26. Emin T. Elmas, & İhsan Ö. Bucak. (2023). Modeling and Simulation of Smart-Drug Algorithms Through Frequency Modulation for the Treatment of Covid-19 and Similar Viruses. Global Journal of Research in Medical Sciences, 3(5), 1–6. https://doi.org/10.5281/zenodo.10051793
27. Emin T. E., & İhsan Ömür B. (2024). FM Modulated Smart Drug Algorithm for the treatment of Cancer Cells. In Global Journal of Research in Medical Sciences (Vol. 4, Number 1, pp. 1–6). https://doi.org/10.5281/zenodo.10463529
28. Emin Taner ELMAS. (2023). Prototype Desıgn, Productıon and Functıonıng of a Portable (Movable), Home-Type (Domestıcal) Hemodıalysıs Machıne (Unıt). In Global Journal of Research in Medical Sciences (Vol. 3, Number 6, pp. 11–12). https://doi.org/10.5281/zenodo.10252972
29. Elmas, Emin Taner (2019) Thermodynamical Balance Associated with Energy Transfer Analysis of the Universe Space as a Pressure Vessel Analogy. Journal of Applied Sciences, Redelve International Publications 2019(1): RDAPS- 10002.
30. Elmas, Emin Taner (2017) Productivity and Organizational Management (The Book) (Chapter 7): Prospective Characteristics of Contemporary Engineer (By the Approach of Mechanical Engineering) Contribution and Role of the Mechanical Engineer to the Organization Management and Productivity. Machado Carolina, Davim J Paulo (Eds.), DEGRUYTER, Walter de Gruyter GmbH, Berlin / Boston, Spain (ISBN:978-3-11-035545-1)
31. Elmas, Emin Taner (2017) Prospective Characteristics of Contemporary Engineer (By the Approach of MechanicalEngineering) Contribution and Role of the Mechanical Engineer to the Organization Management and Productivity). DeGruyter, Germany (DOI 10.1515/9783110355796-007)
32. Emin Taner Elmas. Design of Bio-Artificial Liver Organ. J Biomed Sci Biotech Res. 2024. 2(3): 1-4. DOI: doi.org/10.61440/JBSBR.2024.v2.12
33. ELMAS, E. T. (2024). Design of Bionic Ear-Cochlear Implant and Artificial Hearing System; a Unique Project “Mobile Bio-Ear-Tronic System”. Journal homepage: https://gjrpublication. com/gjrms, 4(02). http://doi.org/10.5281/zenodo.12751385
34. Elmas, Emin Taner, (2014), What Is Expected of the Engineer of Our Era (Çağımızın Mühendisinden Beklenenler), Gece Kitaplığı, ISBN:9786053244158
35. Emin Taner ELMAS* and Levent OĞUL. The Effects of Medicine and Music Therapy Practices on Human Health. IJCMCR. 2025; 50(2): 003, DOI: 10.46998/IJCMCR.2025.50.001233
36. Emin Taner E, Servet K. (2025). Biomechanical Analysis of Transtibial Prosthesis Designed for Runners. Biomedical and Clinical Research Journal, 1(2). Article Identifier: BCRJ/02.2025/007 (the DOI field was published in a non-standard format in the original publication; verification with the publisher is recommended).
37. Emin Taner ELMAS Yavuz ORUÇ; A Novel Mobile Bio-Eye-Tronic System Based on the Elmas’s Thermodynamic Theory for Cataract Disease, Studies in Science of Science, ISSN: 1003-20253, https://doi.org/10.5281/zenodo.18516267, Volume 44, Issue 2, 2026
38. ET Elmas and MA Cinibulak (2025) Fundamental Scientific and Technical Issues related with the “Hip Replacement Design and Biomechanical Analysis”. Journal of Material Science and Nanotechnology, Matsci Nano J, 2025
39. ELMAS, Emin Taner, & KUNDURACIOĞLU, I. (2025). A Model for Second Law of Thermodynamics, Relationship between Health, Disease, Aging, Death Processes and Consciousness, Nervous System and Time. In Global Journal of Research in Medical Sciences (Vol. 5, Number 2, pp. 1–6). https://doi.org/10.5281/zenodo.14973559
40. ELMAS, Emin Taner, & KUNDURACIOĞLU, I. (2025). Metabolic Heat Production with Energy Transfer and Laws of Human Thermodynamics: The Energy Balance of the Human Body. In Global Journal of Research inMedical Sciences (Vol. 5, Number 2, pp. 7–14). https://doi.org/10.5281/zenodo.14973620
41. Elmas ET, Kunduracıoğlu I (2025) Artificial Heart Design and Biomechanical Analysis. Open Access Journal of Medicine and Healthcare, Research Article 1(1): 01-06.
42. ELMAS, Emin Taner, & KUNDURACIOĞLU, I. (2025). Fundamentals of Human Vision System. In Global Journal of Research in Medical Sciences (Vol. 5, Number 2, pp. 103–117). https://doi.org/10.5281/zenodo.15078754
43. ET Elmas (2025) Kitchen Hood Design & Manufacturing Project 3D Modeling, Engineering Calculations, and Technical Drawings for Igdir University Medico Social Building Dining Hall”. Matsci Nano J 1(1): 102.
44. Emin Taner ELMAS, İsmail KUNDURACIOĞLU. Signal Transduction System in Neurons. International Journal of Research in Medical and Clinical Sciences. 2025;3(1): 26-35.
45. Emin Taner ELMAS, İsmail KUNDURACIOĞLU. An Introduction to Sound and Sound Perception System for Human Ear. International Journal of Research in Medical and Clinical Sciences. 2025;3(1): 36-49.
46. Emin Taner ELMAS, İsmail KUNDURACIOĞLU. Medical Structure of the Human Respiratory System. International Journal of Research in Medical and Clinical Sciences. 2025;3(1): 50-63.
47. Emin Taner ELMAS, İsmail KUNDURACIOĞLU. Medical Structure and Hemodynamics of the Human Circulatory System. International Journal of Research in Medical and Clinical Sciences. 2025;3(1): 64-81.
48. Emin Taner ELMAS and İsmail KUNDURACIOĞLU. General Aspects of Advanced Biomechanics. Biomed J Sci & Tech Res 61(5)-2025. BJSTR. MS.ID.009658.

49. Emin Taner Elmas and İs-mail KUNDURACIOĞLU. Conservation Laws and the Main Physical Param-eters for Advanced Biomechanics. Biomed J Sci & Tech Res 61(5)-2025. BJSTR. MS.ID.009659.
50. Emin. T. Elmas, M. Şimşek (2025). Bionic Prosthetic Robotic Artificial Hand Design and Biomechanics Analysis. Journal of Medical Discoveries. RPC Publishers. 2(1); DOI: https://www.doi.org/rpc/2025/rpc.jmd/00311
51. ELMAS ET (2025) Prosthetics, Artificial Limbs, Implants and Their Biomedical Applications. J Surg 10: 11365 DOI:10.29011/2575-9760.011365
52. ELMAS ET (2025) An Introduction to Electrophysical Properties of the Human Heart. J Surg 10: 11364 DOI: 10.29011/2575-9760.011364
53. Elmas, E.T. (2025). A Brief Information about Cataract Operation. European Journal of Science and Modern Technologies, 1(2), 61-66. https://doi.org/10.59324/ejsmt.2025.1(2).05
54. ELMAS, Emin Taner. (2025). A Brief Information about Blood Sugar and Diabetes Management. In ICON Journal of Applied Medical Sciences (Vol. 1, Number 1, pp. 1–5). https://doi.org/10.5281/zenodo.15870465
55. Emin Taner Elmas, Ismail Kunduracioglu. An Introduction to the Medical Body Mechanics and Human Muscles. Journal of Medical and Clinical Case Reports 2(1). https://doi.org/10.61615/JMCCR/2025/APRIL027140418
56. Emin TE, İsmail K (2025) Elastomechanics Fundamentals for Bones and Fractures. Ann Biotech & Biomed Sci 1(1): 1-12.
57. Emin Taner ELMAS, Yavuz ORUC, “An Alternative Non-Surgical Cataract Treatment Method in Medicine and Ophthalmology; “Medi-Ultrasound Eye-Tronic Method””, Universal Library of Medical and Health Sciences, 2025; 3(3): 01-07. DOI: https://doi.org/10.70315/uloap.ulmhs.2025.0303001.
58. Emin Taner ELMAS. System Design and Development of a Novel Unique Neuro-Physical Medical Treatment Method for SMA- Spinal Muscular Atrophy Disease and for Similar Neurological Muscle Diseases. Collect J Neurol. 2024; 1: ART0037. https://doi.org/10.70107/ collectjneurol-art0037
59. Emin Taner ELMAS. Design of Bionic Eye and Artificial Vision System; a Unique Project “Mobile Bio-EyeTronic System”. Collect J Robotics AI. 2024; 1: ART0038. https://doi.org/10.70107/ collectjroboticsai-art0038
60. Elmas, Emin Taner (2025) Productivity and Organizational Management; Management Tools, Human Resource Mangement, Contemporary Engineers (The Book), 2nd Edition; (Chapter 8): Prospective Characteristics of Contemporary Engineer (By the Approach of Mechanical Engineering) Contribution and Role of the Mechanical Engineer to the Organization Management and Productivity. Machado Carolina, Davim J Paulo (Eds.), DEGRUYTER, Walter de Gruyter GmbH, Berlin / Boston, (ISBN:978-3-11-914732-3)
61. Elmas, Emin Taner (2025) Prospective Characteristics of Contemporary Engineer (By the Approach of MechanicalEngineering) Contribution and Role of the Mechanical Engineer to the Organization Management and Productivity). 2nd Edition, DeGruyter, Germany (DOI 10.1515/9783112206775-008)
62. Emin. T. Elmas, M. Şimşek (2025). Bionic Prosthetic Robotic Artificial Hand Design and Biomechanics Analysis. Journal of Medical Discoveries. RPC Publishers. 2(1); DOI: https://www.doi.org/rpc/2025/rpc.jmd/00311s
63. Emin Taner ELMAS and Servet KAYA. The Effect of Eye and Vision on the Body’s Balance System. Biomed J Sci & Tech Res 61(5)-2025. BJSTR. MS.ID.009660.
64. Emin Taner ELMAS, Murat SIMSEK, “A Novel Unique Neuro-Physical Medical Treatment Method for SMA – Spinal Muscular Atrophy Disease, Paralyzed Patients, ALS patients, MPS, SSPE, DMD Patients and for Similar Neurological Muscle Diseases”, Universal Library of Medical and Health Sciences, 2025; 3(3): 32-52. DOI: https://doi.org/10.70315/uloap.ulmhs.2025.0303005.
65. Emin Taner ELMAS, Thermodynamic and Mathematical Model of Human Brain for Neurodegenerative Diseases; Alzheimer’s Disease (AD) Parkinson’s Disease (PD) and Amyotrophic Lateral Sclerosis (ALS). International Journal of Science, Engineering and Technology, 2026, 14:1.
66. Emin Taner ELMAS, The Exploration of Alzheimer’s Disease, along with other Neurodegenerative Disorders like Parkinson’s and ALS, through the lens of Thermodynamics and Physical Sciences involves conducting a Thermodynamic Analysis of Alzheimer’s including the Potential Connections between Treatment methods and the Therapeutic Effects of Musical Sound Frequencies produced by instruments such as the Nây-ı Şerîf, Instrument of Ney (Ney: Turkish Reed Flute, Nay) and others, Gongcheng Kexue Xuebao, Volume 11, No.02, 2026, ISSN 2095-9389
67. Emin Taner Elmas (2025) “Applied Medi-Brain Energy-Tronic Treatment Method” for the Medical Treatments of SMA – Spinal Muscular Atrophy Disease, Paralyzed Patients, ALS Patients, MPS, SSPE, DMD Patients with the Biomechanical Analysis of Bionic Prosthetic Robotic Artificial Hand Design. Journal of Engineering and Applied Sciences Technology. SRC/JEAST-469. DOI: doi.org/10.47363/JEAST/2025(7)335
68. ELMAS, E. T. (2026). Scientific and Technical Introduction to - “Applied Medi-Brain Energy-Tronic Treatment Method”- which is a Novel and Unique Physiological, Neuroengineering and Neuroscientific Medical Treatment Method for SMA – Spinal Muscular Atrophy Disease, Paralyzed Patients, ALS patients, MPS, SSPE, DMD Patients and Other Similar Neurological Diseases. J Psychol Neurosci; 8(1):1-19. DOI: https://doi.org/10.47485/2693-2490.1144

69. ELMAS, E. T. (2026). Thermodynamics and Energy Transfer in Medicine Applications with Archaeomusicology and Music Therapy, Studies in Science of Science | ISSN:1003-205, https://doi.org/10.5281/zenodo.18130664, Volume 44, Issue 1, 2026
70. Emin Taner ELMAS and Ibrahim DAĞ, (2026), Alzheimer Hastalığı ve Parkinson, ALS gibi benzer Nörodejeneratif Hastalıkların, Termodinamik ve Fizik Bilimleri Dahilinde İncelenmesi, Alzheimer Hastalığının Termodinamiksel Analizinin Ortaya Konması ile Ney ve diğer Enstrümanların Ürettiği Müzik Sesi Frekansları ile Tedavinin nasıl İlişkilendirilebileceği Hususunun İncelenmesi (The study of Alzheimer's Disease and similar neurodegenerative diseases such as Parkinson's and ALS within the framework of Thermodynamics and Physical Sciences, the presentation of a thermodynamic analysis of Alzheimer's Disease, and the investigation of how the treatment can be related to the musical sound frequencies produced by the ney and other instruments); Studies in Science of Science | ISSN:1003-2053 https://sciencejournal.re/ | Volume 44, Issue 1, 2026 , https://doi.org/10.5281/zenodo.18302960
71. Emin Taner ELMAS, (2026), Evaluation and Analysis of the Fields of Application of Medical Technique in Science and Engineering in Terms of the Turkish Economy (Bilim ve Mühendislikte Tıp Tekniği Uygulama Alanlarının Türkiye Ekonomisi Yönünden Değerlendirme ve Analizi), Journal of Xidian University https://doi.org/10.5281/Zenodo.18276829 ISSN No:1001-2400, VOLUME 20, ISSUE
72. Emin Taner ELMAS (2026). Thermodynamic Energy Transfer Modeling of Neurodegeneration with the ELMAS's Theory of Thermodynamics which is the Main Scientific Approach for 5th Law of Thermodynamics. Research Paper, 8(3), 1-22. https://doi.org/10.5281/zenodo.19325343
73. Book Editor: Assoc. Prof. Dr. Ahmet Beyzade DEMİRPOLAT, Author: Emin Taner ELMAS - NEW-GENERATION TECHNOLOGIES IN MECHANICAL ENGINEERING: CHAPTER 4: THERMODYNAMIC ANALYSIS OF NEURODEGENERATIVE DISEASES FROM A MECHANICAL ENGINEERING APPROACH AND THEIR TREATMENT WITH MUSIC; A THERMODYNAMIC MODEL FOR ALZHEIMER'S, PARKINSON'S, AND ALS DISEASES (MAKİNE MÜHENDİSLİĞİNDE YENİ NESİL TEKNOLOJİLER: 4. BÖLÜM), E-ISBN: 978-625-382-219-4 DOI: 10.54637/vizetek.9786253822194, Vizetek Publishing, Ankara, 2026
74. Book Editor: Assoc. Prof. Dr. Ahmet Beyzade DEMİRPOLAT, Author: Emin Taner ELMAS - NEW-GENERATION TECHNOLOGIES IN MECHANICAL ENGINEERING: CHAPTER 5: THERMODYNAMIC ANALYSIS OF NEURODEGENERATIVE DISEASES FROM A MECHANICAL ENGINEERING APPROACH AND THEIR TREATMENT WITH MUSIC; MATHEMATICAL MODEL AND CLINICAL OBSERVATIONS IN THE LITERATURE (MAKİNE MÜHENDİSLİĞİNDE YENİ NESİL TEKNOLOJİLER: 5. BÖLÜM), E-ISBN: 978-625-382-219-4 DOI: 10.54637/vizetek.9786253822194, Vizetek Publishing, Ankara, 2026
75. Emin Taner ELMAS. Multifaceted Holistic Medical Health Engineering Combined with Science and Art. International Journal of Research in Medical and Clinical Sciences. 2026; 4(1): 91-102.
76. Emin Taner ELMAS, Book: A Multifaceted Holistic Approach with Science and Art (Bilim ve Sanat ile Çok Yönlü Bütüncül Yaklaşım), ISBN: 978-625-382-263-7, E-ISBN: 978-625-382-264-4, DOI: 10.54637/vizetek.9786253822644, 2026, Vizetek Publishing, Ankara
77. Emin Taner Elmas (2026) Cancer Medical Treatment in Conjuction with the ELMAS's Theory of Thermodynamics which is the Main Scientific Approach for 5th Law of Thermodynamics. Journal of Nanosciences Research & Reports. SRC/JNSRR-228. DOI: doi.org/10.47363/JNSRR/2026(8)186
78. Emin Taner Elmas (2026) Adaptation of AI Simulation Integrated Artificial Heart and Cardiology Appli-cations with ELMAS's Theory of Thermodynamics, which is the Main Scientific Approach to the 5th Law of Ther-modynamics. J of Card Vas Insights 2(2), 01-14. WMJ/JCVI-117
79. Emin Taner Elmas (2026) "Medical Heat Pipes" - "Heat Pipe Applications in Medical Technique" on the Basis of "Elmas's Theory of Thermodynamics and 5th Law of Thermodynamics. Journal of Engineering and Applied Sciences Technology. SRC/JEAST-486. DOI: doi.org/10.47363/JEAST/2026(8)352
80. Traditional Diagnostic Methods of Alzheimer's Disease and Evaluation of Alzheimer's Diagnosis with Blood Tests. International Journal of Research in Medical and Clinical Sciences. 2026; 4(1): 133-146.
81. Emin Taner ELMAS, SCIENCE AND ART with a Multifaceted and Multidisciplinary Holistic Approach, 2026, Vizetek Publishing, Ankara, ISBN: 978-625-382-284-2, E-ISBN: 978-625-382-285-9, DOI: 10.54637/vizetek.9786253822859, Book
82. Emin Taner Elmas (2026) ELMAS's "Energy-Tronic Medical Treatment Methods" based on the princi-ples of Biomechatronics and Neuro-Physics in connection with the Applications of BCI Brain-Computer Interface for Modeling of Neurological Diseases. J. of Adv Clin Neu Res 2(2), 01-17. WMJ/JACNR-120
83. ELMAS, E. T. (2026). DBS - Deep Brain Stimulation Application for Parkinson's Disease on the basis of ELMAS's EnergyTronic System. J Sur & Surgic Proce.,4(2):1-11. DOI: https://doi.org/10.47485/3069-8154.1031
84. ELMAS, E. T. (2026). Engineering-Based Technological Transformation in Dentistry and Endodontics and its Impact on Türkiye's Competitiveness in the Health Tourism Market. International Journal of Medical Science and Dental Health, 12(04), 109-122. https://doi.org/10.55640/ijmsdh-12-04-14
85. Emin Taner ELMAS. (2026) "Application of ELMAS's Theory of Thermodynamics & 5th Law of Thermodynamics for Design and Optimization of ECMO (Extracorporeal Membrane Oxygenation) Machine and Life Support Units ."International Journal of Clinical Case Reports and Clinical Reviews 1(1). Doi: https://doi.org/IJCCRCR .RW .26.002

86. Emin Taner ELMAS. Diagno-sis and Treatment of Internal Bleed-ing with “Medical Thermodynamics” which is the “Medicine of the Future”. Biomed J Sci & Tech Res 65(3)-2026. BJSTR. MS.ID.010192.
87. Emin Taner ELMAS. Design and Optimization of Mobile ECMO (Extracorporeal Membrane Oxygenation) Machine and Life Support Units. International Journal of Research in Medical and Clinical Sciences. 2026; 4(1): 156-166.
88. Emin Taner ELMAS, “-Pancreatic Cancer Diagnosis and Medical Teatment- “ELMAS Medi-Bio-Energy Tronic” Medical Device System Design Study for Pancreatic Cancer Diagnosis Working on the Principle of “ELMAS’s Theory of Thermodynamics” and “5th Law of Thermodynamics” in Connection with Medical Teatment by FM Modulated Bio-Robotic Resonance and Thermodynamical Interaction”, Universal Library of Medical and Health Sciences, 2026; 4(2): 21-44. DOI: https://doi.org/10.70315/uloap.ulmhs.2026.0402004.
89. Emin Taner ELMAS., et al. AI-Enabled Bionic Eye and Artificial Vision System “AI – Enabled Mobile Bio-Eye-Tronic System” Based on the Scientific Framework of "Elmas’s Theory of Thermodynamics" (2026): 02-26.
90. Dr. Emin Taner ELMAS, Artificial Blood Model & Ideal "Super Blood" Model (Optimized Homeostasis) with “ELMAS’s Theory of Thermodynamics and 5 th Law of Thermodynamics including Hemodynamic Principles. Jour of Clin Cas Rep, Med Imag and Heal Sci 14 (4)-2026.
91. Emin Taner ELMAS. Application of “ELMAS's Theory of Thermodynamics” & the “Fifth Law of Thermodynamics” Approach with “Bio-Robotic Resonance and Thermodynamic Interaction Method” for the Medical Diagnosis and Treatment of Colon Cancer (Colorectal Cancer). AJMCRR. 2026; 5(5): 1-25.
92. Emin Taner Elmas. Life Support Units including ECMO Machine, Artificial Kidney (Dialysis), Artificial Liver, Artifical Pancreas, Artificial Lung (Advanced Oxygenator) Applications under a single ELMAS’s Operating System with Integrated Life Support Software “Central Homeostasis Processor”. J Recent Adv Nanomed & Nanotech. 2026; 2(1): 555578.
93. Emin Taner ELMAS1 Engineering Design and Operational Analysis of Cardiopulmonary Bypass (CPB) Machines with the 5th Law of Thermodynamics and ELMAS’s Theory of Thermodynamics.International Journal of Research in Medical and Health Sciences (IJRMHS) 2026. 1(1). 01-10.
94. Emin Taner ELMAS, “Designing a Next-Generation Smart Artificial Cornea from the Perspective of Bio-Robotic Resonance and Medical Thermodynamics: A Multidisciplinary Engineering Approach”, Universal Library of Medical and Health Sciences, 2026; 4(2): 45-57. DOI: https://doi.org/10.70315/uloap.ulmhs.2026.0402005.
95. Emin Taner Elmas (2026) Technical Design Study of a Mobile Portable (Movable), Home- Type (Domestical) Hemodialysis Machine Working as an Artificial Kidney. Journal of Internal Medicine Research & Reports. SRC/JIMRR-171. DOI: doi.org/10.47363/JIMRR/2026(5)155
96. ELMAS, E. T. (2026) The Relationship and Treatment of Autoimmune Diseases, Particularly Thyroid Diseases, with Stress: Bio-robotic Resonance and Thermodynamical Interaction with Analogy of Frequency-Resonance Setting Formation Method and the Use of the 5th Law of Thermodynamics within the Scope of ELMAS’s Theory of Thermodynamics and ELMAS’s Equation. J Psychol Neurosci; 8(3):1-20.
97. Eng C, Yoshino T, Ruíz-García E, et al. Colorectal cancer. Lancet. 2024;404(10449):294–310. DOI: 10.1016/S0140-6736(24)00360-X
98. Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72(2):338–344. DOI: 10.1136/gutjnl-2022-327736
99. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: A Cancer Journal for Clinicians. 2024;74(1):12–49. DOI: 10.3322/caac.21820
100. Darmadi D, Mohammadian-Hafshejani A, Kheiri S. Global disparities in colorectal cancer: unveiling the present landscape of incidence and mortality rates, analyzing geographical variances, and assessing the Human Development Index. J Prev Med Hyg. 2025;65(4):E499–E514. DOI: 10.15167/2421-4248/jpmh2024.65.4.3071
101. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Przegl Gastroenterol. 2019;14(2):89–103. DOI: 10.5114/pg.2018.81072
102. Chu S, Shi X, Tian Y, Gao F. pH-Responsive polymer nanomaterials for tumor therapy. Front Oncol. 2022;12:855019. DOI: 10.3389/fonc.2022.855019
103. Liu Y, Si L, Jiang Y, et al. Design of pH-responsive nanomaterials based on the tumor microenvironment. Int J Nanomedicine. 2025;20:705–721. DOI: 10.2147/IJN.S504629
104. Guo S, Qiao X, Ding L, et al. pH-responsive magnetic Fe_3O_4 modified chitosan nanoparticles loaded with β-acids to improve colorectal cancer treatment. Materials Today Bio. 2025;34:102151. DOI: 10.1016/j.mtbio.2025.102151
105. Mokhtarzadeh A, Hassanpour S, Vahid ZF, et al. Nano-delivery system targeting to cancer stem cell cluster of differentiation biomarkers. J Control Release. 2017;266:166–186. DOI: 10.1016/j.jconrel.2017.09.024
106. Taher M, Susanti D, Haris MS, et al. PEGylated liposomes enhance the effect of cytotoxic drug: a review. Heliyon. 2023;9(2):e13823. DOI: 10.1016/j.heliyon.2023.e13823
107. Grünwald B, Vandooren J, Locatelli E, et al. Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer. J Control Release. 2016;239:39–48. DOI: 10.1016/j.jconrel.2016.08.016
108. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67. DOI: 10.1016/j.cell.2010.03.015

109. Al-Saeedi M, Steinebrunner N, Kudlak A, et al. Novel matrix metalloproteinase-9 (MMP-9) inhibitors in cancer treatment. Int J Mol Sci. 2023;24(15):12133. DOI: 10.3390/ijms241512133
110. Chen Y, Zhao G, Li P, et al. Applications of matrix metalloproteinase-9-related nanomedicines in tumors and vascular diseases. Pharmaceutics. 2025;17(4):479. DOI: 10.3390/pharmaceutics17040479
111. Fu Z, Xiang J. Aptamer-functionalized nanoparticles in targeted delivery and cancer therapy. Int J Mol Sci. 2020;21(23):9123. DOI: 10.3390/ijms21239123
112. Narwade M, Shaikh A, Gajbhiye KR, Kesharwani P, Gajbhiye V. Advanced cancer targeting using aptamer functionalized nanocarriers for site-specific cargo delivery. Biomater Res. 2023;27(1):45. DOI: 10.1186/s40824-023-00365-y
113. Camorani S, Tortorella S, Agnello L, et al. Aptamer-functionalized nanoparticles mediate PD-L1 siRNA delivery for effective gene silencing in triple-negative breast cancer cells. Pharmaceutics. 2022;14(10):2225. DOI: 10.3390/pharmaceutics14102225
114. Ozalp VC, Eyidogan F, Oktem HA. Aptamer-gated nanoparticles for smart drug delivery. Pharmaceuticals. 2011;4(8):1137–1157. DOI: 10.3390/ph4081137
115. Zhu G, Niu G, Chen X. Aptamer-drug conjugates. Bioconjug Chem. 2015;26(11):2186–2197. DOI: 10.1021/acs.bioconjchem.5b00291
116. Vázquez-González M, Willner I. Aptamer-functionalized micro- and nanocarriers for controlled release. ChemNanoMat. 2021;7(9):963–979. DOI: 10.1002/cnma.202100024
117. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. JCO Precis Oncol. 2021;5:PO.20.00349. DOI: 10.1200/PO.20.00349
118. Taieb J, Tougeron D, Taly V, et al. Using circulating tumor DNA in colorectal cancer: current and evolving practices. J Clin Oncol. 2022;40(24):2818–2829. DOI: 10.1200/JCO.21.02615
119. Faulkner LG, Howell LM, Pepper C, et al. The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis. Br J Cancer. 2023;128(2):297–309. DOI: 10.1038/s41416-022-02017-9
120. Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261–2272. DOI: 10.1056/NEJMoa2200075
121. Shim H, Heo S, Sun J. et al. Clinical utility of monitoring circulating tumor DNA using a targeted next-generation sequencing panel in patients with colorectal cancer. Ann Lab Med. 2025;45(4):450–458. DOI: 10.3343/alm.2024.0598. PMC12187491.
122. Giansanti D, Morelli S. Exploring the potential of digital twins in cancer treatment: a narrative review of reviews. J Clin Med. 2025;14(10):3574. DOI: 10.3390/jcm14103574
123. Mollica L, Leli C, Sottotetti F, et al. Digital twins: a new paradigm in oncology in the era of big data. ESMO Real World Data Digit Oncol. 2024;5:100056. DOI: 10.1016/j.esmorw.2024.100056
124. Kemkar S, Tao M, Ghosh A, et al. Towards verifiable cancer digital twins: tissue level modeling protocol for precision medicine. Front Physiol. 2024;15:1473125. DOI: 10.3389/fphys.2024.1473125
125. Asghar US, Chung HC. Application of digital twins for personalized oncology. Nat Rev Cancer. 2025. DOI: 10.1038/s41568-025-00850-7
126. Bouriga R, Bailleux C, Gal J, et al. Advances and critical aspects in cancer treatment development using digital twins. Brief Bioinform. 2025;26:bbaf237. DOI: 10.1093/bib/bbaf237
127. Sánchez-Peralta LF, Glover B, Jha D, Pagador JB. Editorial: Artificial intelligence for early diagnosis of colorectal cancer. Frontiers in Oncology, 14:1495827, 2024. https://doi.org/10.3389/fonc.2024.1495827
128. Boedtkjer E. & Pedersen S.F. (2020). The Acidic Tumor Microenvironment as a Driver of Cancer. Annual Review of Physiology, 82, 103–126. DOI: 10.1146/annurev-physiol-021119-03462710.1146/annurev-physiol-021119-034627 PMID: 31747335
129. Estrella V. et al. (2013). Acidity Generated by the Tumor Microenvironment Drives Local Invasion. Cancer Research, 73(5), 1524–1535. DOI: 10.1158/0008-5472.CAN-12-279610.1158/0008-5472.CAN-12-2796 PMID: 23288510
130. He X. et al. (2018). Acidic tumor microenvironment: a target for smart cancer nano-theranostics. National Science Review, 5(2), 269–288. DOI: 10.1093/nsr/nwx06210.1093/nsr/nwx062
131. Li W. et al. (2022). PEGylated Cisplatin Nanoparticles for Treating Colorectal Cancer in a pH-Responsive Manner. Journal of Immunology Research, 2022, 8023915. DOI: 10.1155/2022/802391510.1155/2022/8023915 PMID: 36061954
132. Hurst N.G. et al. (2007). Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. British Journal of Cancer, 97(7), 971–977. DOI: 10.1038/sj.bjc.660395810.1038/sj.bjc.6603958 PMID: 17848940
133. Dragutinović V.V., Radonjić N.V., Petronijević N.D., Tatić S.B., Dimitrijević I.B., Radovanović N.S., Krivokapić Z.V. (2011). Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) in preoperative serum as independent prognostic markers in patients with colorectal cancer. Molecular and Cellular Biochemistry, 355(1-2), 173-178. DOI:

10.1007/s11010-011-0851-0. PMID: 21541674
134. Tutton M.G. et al. (2003). Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. International Journal of Cancer, 107(4), 541–550. DOI: 10.1002/ijc.1143610.1002/ijc.11436 PMID: 14520690
135. Huang H. (2018). Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances. Sensors, 18(10), 3249. DOI: 10.3390/s1810324910.3390/s18103249 PMID: 30274362
136. Otero-Estévez O. et al. (2015). Serum matrix metalloproteinase-9 in colorectal cancer family-risk population screening. Scientific Reports, 5, 13030.
DOI: 10.1038/srep1303010.1038/srep13030 PMID: 2626906810.1038/srep13030
137. Kessenbrock K., Plaks V. & Werb Z. (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell, 141(1), 52–67. DOI: 10.1016/j.cell.2010.03.01510.1016/j.cell.2010.03.015 PMID: 20371345
138. Chen Y. et al. (2025). Applications of Matrix Metalloproteinase-9-Related Nanomedicines in Tumors and Vascular Diseases. Pharmaceutics, 17(4), 479.
DOI: 10.3390/pharmaceutics1704047910.3390/pharmaceutics17040479
139. Mahmoudian F. et al. (2024). Aptamers as an approach to targeted cancer therapy. Cancer Cell International, 24, 108.
DOI: 10.1186/s12935-024-03295-410.1186/s12935-024-03295-4 PMID: 38486254
140. Zhu L. et al. (2023). Aptamer functionalized nucleic acid nano drug for targeted synergistic therapy for colon cancer. Journal of Nanobiotechnology, 21, 182. DOI: 10.1186/s12951-023-01941-z10.1186/s12951-023-01941-z PMID: 37287003
141. Go G. et al. (2021). PrPC Aptamer Conjugated–Gold Nanoparticles for Targeted Delivery of Doxorubicin to Colorectal Cancer Cells. International Journal of Molecular Sciences, 22(4), 1976.
DOI: 10.3390/ijms2204197610.3390/ijms22041976 PMID: 33671286
142. Pytlíková S. et al. (2025). Dual Thermo- and pH-Responsive Polymer Nanoparticle Assemblies for Potential Stimuli-Controlled Drug Delivery. ACS Applied Bio Materials, 8(1), 271–284.
DOI: 10.1021/acsabm.4c0116710.1021/acsabm.4c01167 PMID: 39661715
143. Biabanikhankahdani R. et al. (2016). pH-responsive Virus-like Nanoparticles with Enhanced Tumour-targeting Ligands for Cancer Drug Delivery. Scientific Reports, 6, 37891.
DOI: 10.1038/srep3789110.1038/srep37891 PMID: 27892517
144. Rachamala H.K. et al. (2025). Translational Advances in Lipid Nanoparticle Drug Delivery Systems for Cancer Therapy: Current Status and Future Horizons. Pharmaceutics, 17(10), 1315.
DOI: 10.3390/pharmaceutics1710131510.3390/pharmaceutics17101315
145. Ottaiano A. et al. (2025). Genomic trajectories of colorectal cancer with choroidal metastasis: longitudinal insights from tissue and liquid biopsy via next-generation sequencing. Frontiers in Genetics, 16, 1632580.
DOI: 10.3389/fgene.2025.163258010.3389/fgene.2025.1632580
146. Parigger T, Gassner F.J., Drothler S. et al. (2024). Combined DNA Analysis from Stool and Blood Samples Improves Tumor Tracking and Assessment of Clonal Heterogeneity in Localized Rectal Cancer Patients. Technology in Cancer Research & Treatment, 23. doi: 10.1177/15330338241252706. PubMed, PMID: 38766867
147. Giansanti D. & Morelli S. (2025). Exploring the potential of digital twins in cancer treatment: a narrative review of reviews. Journal of Clinical Medicine, 14(10), 3574. DOI: 10.3390/jcm1410357410.3390/jcm14103574
148. Asghar U.S. & Chung C. (2025). Application of digital twins for personalized oncology. Nature Reviews Cancer, 25, 823–825. DOI: 10.1038/s41568-025-00850-710.1038/s41568-025-00850-7
149. Lee C.J. et al. (2026). The dysadherin/carbonic anhydrase 9 axis shapes an acidic tumor microenvironment to promote colorectal cancer progression. Signal Transduction and Targeted Therapy, 11(1), 1–18.
DOI: 10.1038/s41392-025-02543-x10.1038/s41392-025-02543-x
150. Chu S. et al. (2022). pH-Responsive Polymer Nanomaterials for Tumor Therapy. Frontiersin Oncology, 12, 855019.
DOI: 10.3389/fonc.2022.85501910.3389/fonc.2022.855019 PMID: 35402266
151. Liu Y. et al. (2025). Design of pH-responsive nanomaterials based on the tumor microenvironment. International Journal of Nanomedicine, 20, 705–721. DOI: 10.2147/IJN.S50462910.2147/IJN.S504629
152. Guo S. et al. (2025). pH-responsive magnetic Fe_3O_4 modified chitosan nanoparticles loaded with β-acids to improve colorectal cancer treatment. Materials Today Bio, 34, 102151.
DOI: 10.1016/j.mtbio.2025.10215110.1016/j.mtbio.2025.102151
153. Park D. et al. (2024). Aptamer-Based Smart Targeting and Spatial Trigger–Response Drug-Delivery Systems for Anticancer Therapy. Biomedicines, 12(1), 187.
DOI: 10.3390/biomedicines1201018710.3390/pharmaceutics16010122 PMID: 38276492
154. Wen X. et al. (2024). Development of an aptamer capable of multidrug resistance reversal for tumor combination chemotherapy. Proceedings of the National Academy of Sciences USA, 121(15), e2321116121.
DOI: 10.1073/pnas.2321116121 10.1073/pnas.2321116121 PMID: 38557177
155. Narwade M. et al. (2023). Advanced cancer targeting using aptamer functionalized nanocarriers for site-specific cargo delivery. Biomaterials Research, 27(1), 42.
DOI: 10.1186/s40824-023-00365-y10.1186/s40824-023-00365-y PMID: 37165416

156. Ullah F. et al. (2022). Formulation Development and Characterization of pH Responsive Polymeric Nano-Pharmaceuticals for Targeted Delivery of Anti-Cancer Drug (Methotrexate). Frontiers in Pharmacology, 13, 911771. DOI: 10.3389/fphar.2022.91177110.3389/fphar.2022.911771 PMID: 35865956
157. Kordkatouli M. et al. (2024). Recent Progress in Nanoparticle-Driven Drug Delivery Strategies for Cancer Therapy: Focus on Colorectal Cancer. Zahedan Journal of Research in Medical Sciences, 27(1), e158109. DOI: 10.5812/zjrms-15810910.5812/zjrms-158109
158. Suzuki T, Suzuki T, Yoshimura Y. et al. (2020). Detection of circulating tumor DNA in patients of operative colorectal and gastric cancers. Oncotarget, 11(34):3198–3207. doi: 10.18632/oncotarget.27682. PMC7456613.
159. Hansen E. & Read A.F. (2020). Modifying Adaptive Therapy to Enhance Competitive Suppression. Cancers, 12(12), 3556. DOI: 10.3390/cancers1212355610.3390/cancers12123556 PMID: 33260699
160. Mollica L. et al. (2024). Digital twins: a new paradigm in oncology in the era of big data. ESMO Real World Data and Digital Oncology, 5, 100056. DOI: 10.1016/j.esmorw.2024.10005610.1016/j.esmorw.2024.100056
161. Elmas, E. T. (2026). ELMAS thermodynamic theory and FM-modulated biorobotic resonance approach for the early diagnosis and treatment of pancreatic cancer. *Frontiers in Research*, *6*(3), 186–203. https://doi.org/10.71350/30624533144
162. Emin Taner ELMAS; Modern Mühendislik Yaklaşımları / Modern Approaches in Engineering, Kitap Bölüm 5: - "ELMAS'IN TERMODİNAMİK TEORİSİ" VE "TERMODİNAMİĞİN 5. YASASI" PRENSİPLERİNE DAYALI PANKREAS KANSERİ TANISI VE TIBBİ TEDAVİSİ- *Kısım – 1: ("ELMAS Medi-Bio-Energy Tronic" Tıbbi Cihaz Sistemi Tasarım Çalışması: Pankreas Kanseri Tanısı için "ELMAS'ın Termodinamik Teorisi" ve "Termodinamiğin 5. Yasası" prensiplerine dayalı, FM Modüle Edilmiş Biyo-robotik Rezonans ve Termodinamik Etkileşim ile Tıbbi Tedavi bağlantılı Metodolojik Sistem Dizaynı), 2026, Vizetek Yayıncılık, Ankara, E-ISBN: 978-625-382-319-1 , DOI: 10.54637/vizetek.9786253823191, Editör Doç. Dr. Emre ARABACI*
163. Emin Taner ELMAS; Modern Mühendislik Yaklaşımları / Modern Approaches in Engineering, Kitap Bölüm 6: - "ELMAS'IN TERMODİNAMİK TEORİSİ" VE "TERMODİNAMİĞİN 5. YASASI" PRENSİPLERİNE DAYALI PANKREAS KANSERİ TANISI VE TIBBİ TEDAVİSİ- *Kısım – 2: ("ELMAS Medi-Bio-Energy Tronic" Tıbbi Cihaz Sistemi Tasarım Çalışması: Pankreas Kanseri Tanısı için "ELMAS'ın Termodinamik Teorisi" ve "Termodinamiğin 5. Yasası" prensiplerine dayalı, FM Modüle Edilmiş Biyo-robotik Rezonans ve Termodinamik Etkileşim ile Tıbbi Tedavi bağlantılı Yapay Zekâ Entegrasyonu), 2026, Vizetek Yayıncılık, Ankara, E-ISBN: 978-625-382-319-1, DOI: 10.54637/vizetek.9786253823191, Editör Doç. Dr. Emre ARABACI*
164. Emin Taner ELMAS; Makine Mühendisliği Alanında Uluslararası Araştırmalar-V / International Research in the Field of Mechanical Engineering; Kitap Bölümü:"ELMAS'IN TERMODİNAMİK TEORİSİ VE HEMODİNAMİK PRENSİPLERİ DAHİLİNDE TERMODİNAMİĞİN 5. YASASI" İLE BİRLİKTE YAPAY KAN MODELİ VE İDEAL "SÜPER KAN" MODELİ (OPTİMİZE EDİLMİŞ HOMEOSTAZ), *2026, Eğitim Yayınevi, ISBN: 978-625-8824-24-7 E-ISBN: 978-625-8824-25-4, Editör: Prof. Dr. Murat Makaracı*
165. Emin Taner ELMAS; Makine Mühendisliği Alanında Uluslararası Araştırmalar-V / International Research in the Field of Mechanical Engineering; Kitap Bölümü, "MEKANİK REHABİLİTASYON" VE "BİYONİK YAPAY ORGANLAR" İLE MAKİNA MÜHENDİSLİĞİNDE YENİLİKÇİ TIP TEKNİĞİ UYGULAMALARI *2026, Eğitim Yayınevi, ISBN: 978-625-8824-24-7 E-ISBN: 978-625-8824-25-4, Editör: Prof. Dr. Murat Makaracı*
166. Emin Taner ELMAS, "Glioblastoma – Beyin Kanseri - Tedavisinde Termodinamiğin 5. Yasası Tabanlı Kapalı Döngü Geri Beslemeli Biyo-Robotik Rezonans Yöntemi ve FM Modüle Akıllı İlaç Algoritması" ("Closed-Loop Feedback Bio-Robotic Resonance Method and FM Modulated Smart Drug Algorithm Based on the 5th Law of Thermodynamics in Glioblastoma - Brain Cancer- Treatment"), 10.43681/Limite.2026.V16I6.72701, Limite Journal | ISSN:1888-4067/E-ISSN:2253-7929, Volume 16 Issue 7, 2026
167. Elmas, E. T., & Akçin, F. (2026). ELMAS temelli yapay zekâ ve nanoteknoloji destekli çok katmanlı akıllı ilaç sistemi ile kolorektal kanserin erken tespiti ve hedefli tedavisi. *Advanced Research Journal*, *13*(4), 10–50. https://doi.org/10.71350/30621925123